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The cancers of liver, colon and breast are amongst the top five most prevalent and most
fatal worldwide. Currently, surgical resection, radiotherapy and adjuvant chemotherapy, in some
cases combined with certain approved targeted agents, constitute the front line therapies for
hepatocellular carcinoma (HCC) and colorectal cancer (CRC). As the Raf/MEK/ERK pathway is
frequently deregulated in HCC, sorafenib, a Raf kinase inhibitor, became the first systemic
therapy approved for the treatment of patients with HCC. However, sorafenib only produced
modest effects with low response rates in the clinic. Similarly, regorafenib, a more potent and
more soluble derivative of sorafenib, which was approved for the treatment of metastatic CRC,
has had a poor response rate in the clinic. Since phosphodiesterase type 5 has been reported to be
overexpressed in HCC and CRC, we hypothesized that sildenafil, a phosphodiesterase type 5
inhibitor, could enhance the toxicities of sorafenib and regorafenib in HCC and CRC cells,
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respectively. Our in vitro data indicated that the drugs interacted strongly to kill cancer cells via
induction of ER stress, autophagy and apoptosis. In accordance with these findings, our in vivo
data demonstrated a significant reduction in tumor growth.
The second study was conducted based on the growing body of evidence about the
significant contribution of EGFR and JAK/STAT signaling to the breast tumorigenesis. Thus, we
hypothesized that the concurrent inhibition of JAK/STAT and EGFR signaling pathways would
kill breast cancer cells in a synergistic manner. Our preliminary in vitro data demonstrated that
the inhibition of these two pathways by lapatinib, a dual ERBB1/2 inhibitor, and ruxolitinib, a
JAK1/2 inhibitor, synergistically killed breast cancer cells of all types, including the resistant
triple negative subtype. Our mechanistic studies showed that the combination of ruxolitinib and
lapatinib triggered cytotoxic mitophagy, and autophagy-dependent activation of BAX and BAK
leading to the mitochondrial dysfunction.
Collectively, our studies strongly argue that the combination of sorafenib/regorafenib and
sildenafil as well as the combination of ruxolitinib and lapatinib can possess significant
therapeutic value in the clinic.
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CHAPTER 1: Introduction to Cancer Therapy
Cancer
Cancer is a complex compilation of distinct genetic abnormalities, which collectively
alter the way normal cells, in a particular part of the body, function, grow and divide.1 Consistent
with Darwinian principles, cancer stems from random mutations within the genes of normal cells
in a multistep process that enable these cells to activate or modify certain cellular programs,
including proliferation, migration and apoptosis.1,2 These mutagenic alterations occur in the form
of activating (gain-of-function) mutations, amplification and/or overexpression of genes that
promote proliferation (oncogenes), as well as inactivating (loss-of-function) mutations, deletion
and/or epigenetic silencing of genes that inhibit growth (tumor suppressor genes).1,3 Many
studies have concluded that both intrinsic naturally-occurring errors in DNA replication and
extrinsic factors, such as exposure to carcinogens, can affect the rate of mutagenesis although it
is not very well clear what portion of total cancer risk stems from each source.4
Despite the variable genetic profile of cancer cells, they share common biological
characteristics, which have been referred to as the hallmarks of cancer. According to Hanahan
and Weinberg2, these acquired capabilities that distinguish cancer cells from the normal cells
include activating proliferative signaling, inhibiting growth suppressors, resisting cell death,
gaining replicative immortality, promoting angiogenesis, and activating invasion and metastasis.
In addition to the acquisition of the hallmark traits, which are highlighted as the major
driving force behind carcinogenesis, the cancer cells also possess the capability to recruit the
surrounding stromal cells to form a histologically diverse microenvironment that enhances
growth, progression and metastasis.1,2 In other words, a tumor is not simply a homogenous
aggregate of cancer cells but rather a more complex heterogeneous population of cells, including
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cancer cells, cancer stem cells, immune inflammatory cells, endothelial cells and cancerassociated connective tissue.1,2 The formation of this advanced microenvironment around the
cancer cells adds another layer of complexity to understanding the mechanisms of tumorigenesis,
and implies that the tumor biology cannot be fully understood without studying the individual
cells within it.2
Currently, cancer is the second leading cause of death worldwide behind the
cardiovascular diseases. In the United States, a quarter of all deaths are caused by cancer, and
new statistics suggest that nearly half of men (~45%) and a third of women (~38%) in the United
States will be affected by this fast-growing disease during their lifetimes.5,6 The cancers of lung,
colorectum, prostate and breast continue to be among the deadliest, accounting for half of the
cancer-related mortalities in American men and women.6 On the bright side, due to the advent of
new therapies, a decrease in tobacco consumption, more effective screening and early detection,
cancer death rates dropped 22.9% in men and 15.3% in women between 1990-2008.6
A Concise History of Cancer Treatment
A great body of evidence suggests that cancer is not a disease of modern era as
paleopathologic findings revealed that cancer existed in prehistoric times, long before human
species evolved.7 The earliest case of cancer in humans was found in Edwin Smith Papyrus
dating back to approximately 3000 BC, being described as an incurable grave disease.7 Similar
reports of cancer cases were found in ancient Egyptian manuscripts.5 The Egyptians utilized
cautery, knives, salts and arsenic paste as means of treatment whereas the Sumerians, Chinese,
Indians and Persians resorted to herbal remedies.7 Later the Romans treated aggressive cancers
by surgical resection, or amputation in more severe cases, followed by herbal remedies. This
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approach remained to be the standard procedure in cancer treatment before the Catholic Church
prohibited all surgical operations in 1215.5,7
The major breakthrough in cancer therapy came at the turn of the 20th century by an
accidental observation of the effect of mustard gas on the depletion of bone marrow and lymph
nodes. Supported by further studies, the use of nitrogen mustard as a treatment for lymphoma
increased rapidly in the United States. A few years later, it was discovered that folate deficiency
could replicate the effects of nitrogen mustard on bone marrow. These findings triggered the use
of synthesized anti-folate drugs, most notably methotrexate, as a treatment for leukemia.8
In the middle of 1950s, Charles Heidelberger and his colleagues noticed a significant
increase in uracil uptake by hepatoma cells relative to normal tissue. Their efforts resulted in the
synthesis of 5-fluorouracil (5-FU), which was later utilized against a broad range of solid tumors.
Their approach to target a certain biochemical pathway that cancer cells relied upon was the very
first example of what we refer to as targeted therapy today.8,10
The initial optimism of curing cancer with the use of alkylating agents and
antimetabolites soon turned into disappointment as many cases of recurrence and metastasis were
reported in the patients. In late 1960s, cancer treatment moved towards combination
chemotherapy, and chemotherapeutics were applied in conjugation with surgery and/or
radiation.8,9 In adjuvant therapy, the chemotherapy is administered after surgery to eliminate the
remaining cancer cells whereas in neoadjuvant therapy, the chemotherapy is applied before
surgery in order to reduce the size of the tumor.5,9
Eventually in the late 20th century, through the advancements in genomics, many
oncogenes and tumor suppressor genes were identified. The genome sequencing of a variety of
cancer cells suggested that many of them possessed abnormalities within genes that coded for
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protein kinases. Subsequently, a new class of anti-cancer therapeutics known as kinase inhibitors
was soon developed. These small molecules are believed to hold significant promise to treat all
sorts of malignancies as they aim at specific targets within the cancer cells and have the
capability to exploit oncogene addiction.8,11,14 The development of imatinib (Gleevec) against the
aberrant nonreceptor tyrosine kinase Bcr-Abl in patients diagnosed with chronic myeloid
leukemia (CML) is a perfect example of targeted therapy as complete responses were observed
in 60-70% of cases.8,12,14 In addition to kinase inhibitors, monoclonal antibodies such as
trastuzumab (Herceptin) and antisense inhibitors have also been developed and studied during
the past two decades. Currently, the efficacy of many of these targeted drugs in a variety of
cancers is being evaluated in the clinic, both individually and in combination with other targeted
or chemotherapy agents.
Targeted Therapy
Chemotherapy has been the cornerstone of cancer therapy for decades; however, its
response rate remains low as most cytotoxic chemotherapeutics yielded narrow therapeutic
index, caused significant toxicity, and resulted in palliative, unpredictable responses.
Furthermore, poor penetrability, low absorption, rapid elimination, development of drug
resistance, and the complex heterogeneous nature of the tumor microenvironment contributed to
their dysfunctionality.12,13,23 Therefore, a more target-specific approach based on better
understanding of the tumor biology started to take root in the post-genomic era. Since all drugs
have targets, the term targeted therapy might be misleading. Therefore, we need to define this
category of therapies first before making any comparisons to the conventional chemotherapy.
Targeted therapy refers to treatments, in which a target within the cancer cells, cancer
stem cells, or the tumor microenvironment is first identified, before a selective inhibitory drug is
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developed against it. The development of Herceptin against Her-2/Neu, an oncogenic receptor
tyrosine kinase involved in progression of Her-2 positive breast cancer, is just an example
amongst many.10 Evidently, the major benefit of this type of tailored therapy is that it only
interferes with distinct molecular targets that the cancer cells physiologically depend on, thus,
providing high specificity, a broader therapeutic index, and less nonspecific toxicities.12
Antiangiogenic drugs are another class of targeted therapeutics that has been broadly
explored in recent years. It has been well established that tumor blood supply is critical for tumor
progression and metastasis.19,21 One of the key mediators of angiogenesis is known to be
vascular endothelial growth factor-A (VEGF-A). Inhibition of angiogenic factors such as VEGFA have appeared to be an effective approach with near universality application and minimal
incidences of acquired resistance.14,15,19 Bevacizumab is a great representative of this class of
drugs, which binds to VEGF with high specificity thus inhibiting angiogenesis. Recent clinical
trials have approved the effects of Bevacizumab in combination with 5-fluorouracil in extending
survival rate in patients with metastatic colorectal cancer.15,21 Similarly, kinase inhibitors with
anti-VEGF receptor (VEGFR) activity such as sorafenib have produced impressive results in
treating renal cell carcinoma.14,12,20
Drug Resistance in Cancer
Although the cancer genome profile is genuinely a useful tool that identifies most
oncoprotein/tumor suppressor-related mutations, producing Gleevec-like success in most solid
tumors through targeted therapy has been proven to be extremely challenging. In fact, over 90%
of the targeted compounds in clinical trials fail to gain approval due to their poor efficacy.10,14
Two major reasons have been proposed to have caused this subpar results.
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Firstly, it is extremely difficult to distinguish the mutations that occur early in the life of a
tumor from the ones that occur in the later stages. This can severely affect the dependency of a
tumor on a certain mutation and the degree by which an inhibitory agent can block tumor
growth. For instance, in case of CML, the abnormality in Bcr-Abl tyrosine kinase is generally
agreed to be the initiating mutation, to which the significant success of Gleevec is attributed.14,18
In contrast, there is evidence suggesting that the activating mutation in FMS-like tyrosine kinase
3 receptor (FLT3) in patients with acute myeloid leukemia (AML) occurs later in tumor
progression. Therefore, the phase I studies of FLT3 targeted inhibitors have not replicated the
impressive response rate of Gleevec.14,16,17,18
Secondly, the emergence of different forms of acquired resistance in cancer cells against
the cytotoxic chemotherapeutics and the targeted drugs have been largely to blame for their
dismal response rate. Here we briefly discuss some of the major mechanisms of resistance
acquired in response to both targeted and chemotherapy.
1. Increased expression of drug efflux pumps: among all transporter proteins, the ATPbinding cassette (ABC) transporter family of transmembrane proteins has been most notably
linked to multi drug resistance (MDR). This protein family consists of 49 members, grouped into
seven subfamilies (designated A to G) that are involved in transportation of a broad range of
substrates, including amino acids, ions, lipids, sugars and drugs across the membrane.23-26 Multidrug resistance protein 1 (MDR1, also known as ABCB1), MDR-associated protein 1 (MRP1,
also known as ABCC1) and breast cancer resistance protein (BCRP, also referred to as ABCG2)
are the 3 members of this family that are overexpressed in many cancers. These transporters can
efflux a wide range of chemotherapeutics such as taxanes, topoisomerase inhibitors and
antimetabolites.23,24,26 Statistical studies have established a correlation between increased

9
expression of ABC transporters and a poor response to chemotherapy.27 For instance, the low
response rate to anthracyclines in pancreatic cancer has been suggested to be in part due to the
MDR phenotype.28,29 In spite of the initial optimism, the combination of the inhibitors of these
transporters with the standard of care chemotherapy generated disappointing results. For
instance, the combination of valspodar, a specific ABCB1 inhibitor, in combination with
paclitaxel and carboplatin in patients with stage IV ovarian or primary peritoneal cancer did not
yield any benefit as compared to chemotherapy alone.24,30 These findings argued that the
contribution of MDR phenotype to drug resistance might not be as significant as previously
presumed.23,24
2. Drug inactivation: another obstacle in cancer therapy is diverse cellular mechanisms
of drug inactivation or insufficient drug activation. Resistance to the platinum drugs such as
cisplatin by glutathione is a good example of such inactivation mechanisms.31 Epigenetic
silencing can also contribute to the activity of certain drugs.23 For instance, o6-methylguanineDNA methyltransferase (MGMT) is a repair enzyme whose function counteracts the formation
of DNA double strand breaks induced by temozolomide (TMZ) in patients suffering from
glioblastoma multiforme (GBM). The clinical studies have indicated that the methylated status of
MGMT promoter in GBM patients who received concurrent radiotherapy and TMZ treatment
was associated with a significant increase in survival time as this group of patients lived on
average 6.4 months longer than the patients who possessed normal MGMT expression level.32,33
3. Secondary mutations in drug targets: drug resistance can also stem from the
secondary somatic alterations within the oncogenic targets. The first case of this resistance
mechanism was identified in CML patients treated with Gleevec, and similar genetic alterations
have been observed in other cancers ever since.22,23 In general, these mutations either promote an
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active enzymatic conformation or the target or prevent drug binding.22 One of The best examples
of such target alterations is the gatekeeper mutations within the catalytic domain of epidermal
growth factor receptor (EGFR) in patients with non-small cell lung cancer (NSCLC), which
increases the affinity of EGFR for ATP, thus lowering the efficacy of EGFR inhibitors. These
alterations have been directly linked to the dramatic response rates of erlotinib and gefitinib in
patients with NSCLC.22,23,34
4. DNA damage repair: Most chemotherapeutics cause DNA damage either directly as
seen by platinum drugs or indirectly as observed by the function of topoisomerase inhibitors.
Therefore, the capacity of DNA damage repair in cancer cells, as explained by the
aforementioned example of MGMT in TMZ therapy, plays a critical role in the response rate of
chemotherapy.23,33 Thus, targeting the components of the DNA repair machinery has emerged as
a new strategy to enhance the toxicity of chemotherapeutics. The development of poly (ADPribose) polymerase 1 (PARP1) inhibitors exemplifies this targeted approach. PARP1 is a
ubiquitous single-strand-break DNA repair enzyme, and its inhibition results in accumulation of
single-strand breaks followed by double-strand breaks.23,35 A phase I trial of olaparib, a potent
PARP1 inhibitor, in patients with breast and ovarian cancer, including carriers of mutated
BRCA1 and BRCA2 genes, generated positive results.36 There are also ongoing clinical trials
evaluating the effect of olaparib in combination with chemotherapy in all solid tumors.35
5. Deregulation of apoptotic components: as previously mentioned, resistance to cell
death is one of the hallmarks of cancer, thus it is evident that deregulation of apoptosis is one of
the mechanisms of drug resistance utilized by cancer cells. This deregulation can occur in both
pro-apoptotic and anti-apoptotic components of the programmed cell death. Previous studies
have

reported

that

overexpression

of

anti-apoptotic

proteins

caused

resistance

to
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chemotherapeutics in leukemic cells.23,37 Studies from our laboratory also suggested that
lapatinib-resistant HCT116 cells had higher expression of anti-apoptotic proteins Bcl-xL and
Mcl-1 and reduced expression of pro-apoptotic protein BAX compared to the wild type cells, and
that inhibition of Mcl-1 restores lapatinib toxicity to a great extent.38
6. Activation of pro-survival signaling pathways: the activation of survival pathways
in response to chemotherapy is another way for cancer cells to resist cell death. Plenty of studies
have proposed the activation of EGFR as a resistance mechanism to chemotherapy.23 Similar
studies indicated that EGFR inhibitors could enhance the effects of paclitaxel and 5-FU in renal
and colorectal cancer, respectively.39,40 Furthermore, some clinical trials have supported the
beneficial addition of EGFR inhibitors to irinotecan-based therapy, leading to approval of these
targeted agents by the Food and Drug Administration (FDA) for treatment of certain subtypes of
colorectal cancer.23,41
7. Activation of bypass mechanisms: activation of compensatory parallel signaling
pathways has emerged as a major concern rendering cells resistant to targeted therapy. In this
mechanism of resistance, also referred to as oncogenic bypass, activation of an alternative kinase
through an adaptive feedback loop or a secondary mutation triggers signaling through parallel
pro-survival pathways, which ultimately counteracts the effect of the targeted agent.22,23 A good
example of this type of resistance is the activation of ERBB3 and its downstream PI3K/AKT
pathway in response to EGFR inhibitors such as cetuximab.42,43 Similar mechanism has been
reported in patients with NSCLC that responded poorly to gefitinib, as an amplification of MET
proto-oncogene led to the activation of ERBB3 compensatory signaling.44
Advantages of Combinatorial Targeted Therapy
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Investigating the various mechanisms of drug resistance undoubtedly provides a plethora
of information that can be directed towards the development of more effective future therapies.
For example, the increased affinity of the mutant EGFRT790M for ATP in patients with NSCLC
has led to the production of new restructured irreversible inhibitors that bind to EGFR catalytic
cleft more readily than erlotinib and gefitinib. This new generation of EGFR inhibitors have
shown improved efficacy in murine models.22,45 However, most types of acquired resistance are
mediated by the activation of the alternative compensatory pathways rather than alteration of the
drug target itself. Therefore, resorting to a rational combinatorial approach seems imperative.
There are two distinct types of drug combinations:
1. Combinations of targeted drugs with chemotherapy: many studies have recently
indicated that the specific targeted agents can enhance the effect of chemotherapy in a variety of
tumor types through interference with the DNA repair enzymes or inhibition of pro-survival
pathways. The FDA-approved combination of lapatinib with capecitabine in women with
advanced breast cancer resistant to trastuzumab, or the combination of cetuximab with irinotecan
in patients with metastatic colorectal carcinoma are two examples of how the targeted inhibition
of an activated survival pathway leads to a more responsive chemotherapy.11,41,46 Concurrent
inhibition of DNA repair enzymes (e.g. PARP1) or checkpoint kinases (e.g. CHK1) with
chemotherapy has also significantly improved the standard of care in a variety of cancers.35,47
2. Combinations of target-specific drugs: a major setback to single-agent targeted
therapy is the potential for crosstalk between pro-survival pathways. This may result in the cell
activating an alternative survival pathway in the event of blockade of a specific pathway; thus,
leading to drug resistance. Therefore, there is growing evidence that the use of targeted
therapeutics in combination provides a more rational strategy to increase the efficacy of
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treatment. The combinatorial targets might lie within the same oncogenic pathway (referred to as
vertical) or located within two distinct pathways (described as horizontal).11 For instance, recent
clinical trials revealed that EGFR inhibitors, used as single agents, are of little therapeutic benefit
in patients with GBM, which commonly possess deregulated EGFR signaling pathway.48 One of
the mechanisms of resistance to EGFR inhibition in GBM cells has been shown to be the
upregulation of platelet-derived growth factor receptor β (PDGFRβ).49 A recent study from our
laboratory indicated that the addition of sorafenib, a multi-kinase inhibitor with anti-PDGFRβ
activity, significantly enhances lapatinib toxicity in GBM cells.50 Another relevant example is
the crosstalk between estrogen receptors (ER) and EGFR family members, which has been
shown to modulate resistant to hormone therapy.51,52 These findings led to accelerated approval
of lapatinib in combination with letrozole, an aromatase inhibitor, for the treatment of
postmenopausal women with ER-positive metastatic breast cancer.53
The purpose of this study is to introduce novel targeted drug combinations in multiple
types of cancer using the same rationale. But prior to presenting the results, we need to introduce
some of the important signaling pathways involved in survival and cell death, which are affected
by the proposed drug combinations in this manuscript.
Mitogen-Activated Protein Kinase Pathway (MAPK)
MAPK pathways are evolutionary conserved signaling cascades involved in fundamental
intracellular processes such as growth, proliferation, migration and apoptosis. MAPK pathways
consist of a three-tier kinase module in which a downstream MAPK is activated upon
phosphorylation by MAPK kinase (MAPKK), which in turn is activated when phosphorylated by
its upstream MAPK kinase kinase (MAPKKK). There are four major well characterized
mammalian MAPK kinase pathways that activate four distinct terminal serine/threonine kinases,
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ERK1/2, c-Jun amino-terminal kinase (JNK), p38 kinase and ERK5 (Figure 1).54-56 ERK1/2 is
normally activated by growth factors whereas JNK, p38 and ERK 5 usually become activated in
response to cytokines or environmental stress such as osmotic shock and ionizing radiation.
Recently, two more mammalian MAPK pathways have been discovered that lead to activation of
ERK3/4 and ERK 7/8 while the rest of the components of these pathways are currently
unknown.54-56 Among all, the ERK1/2 MAPK signaling pathway, commonly deregulated in
many cancers, has drawn a great deal of attention due to its pivotal role in vital cell functions
including growth, differentiation, survival, migration and angiogenesis, and has grown as a major
target for cancer drug discovery.54-57 Deregulation of this pathway occurs at several different
levels as the mutational activation of Raf, Ras and their upstream receptors such as EGFR has
been reported in a variety of human cancers.54,55
p38 is strongly responsive to pro-inflammatory cytokines and environmental stress, and
gets activated by two main MAPKKs, MKK3 and MKK6. Two main substrates of p38 are MAP
kinase-activated protein kinase 2 (MK2) and MK3. Activated MK2 and MK3 interact with
various targets, including heat shock protein (HSP) 27, CREB, and ATF.58,59
The JNK kinase family (also known as stress-activated protein kinases (SAPK)) includes
three proteins JNK1, JNK2 and JNK3, which get activated by MKK4 and MKK7 in response to
cytokines, growth factors and stress. Upon activation, JNKs interact with numerous substrates,
most prominently the transcription factor activator protein-1 (AP-1), which is formed by
dimerization of the Fos and Jun proteins.60,61
JNKs and p38 MAPKs regulate many pathways involved in inflammation, proliferation,
differentiation, survival and cell death. They can act both as tumor suppressors and oncoproteins
depending on cell type, duration of activation and the nature of stimulus.60,62
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Figure 1. Four major mammalian MAPK pathways. MAPK pathways are comprised of threetier kinase module in which a MAPKKK phosphorylates the downstream MAPKK, which in turn
phosphorylates its downstream serine/threonine MAPK. Among the MAPKs activated by these
four pathways, only ERK1/2 responds to growth factors. ERK5, JNK and p38 are mainly
activated due to environmental stress such as osmotic shock and ionizing radiation.
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Ras/Raf/MAPK Pathway
When growth factors bind to their receptors, they induce dimerization and autophosphorylation of tyrosine residues on the catalytic domains of these receptors. These phosphotyrosines act as docking sites for growth factor receptor-bound protein 2 (GRB2), an adaptor
protein, and sons of sevenless (SOS), an exchange factor, which together result in the activation
of Ras (Figure 2).55,57,63
Ras GTPases (H-, K- and N-Ras) act as molecular switches that mediate activation of
many signaling pathways. Inactive guanosine diphosphate (GDP)-bound Ras activity is regulated
by guanine nucleotide exchange factors (GEFs), such as SOS, which promote the formation of
active guanosine triphosphate (GTP)-bound Ras, whereas GTPase-activating proteins (GAPs),
such as neurofibromin 1 (NF1), induce GTP hydrolysis and formation of inactive GDP-bound
Ras. Activated GTP-bound Ras then recruits Raf from the cytosol to the cell membrane where a
multi step activation process occurs.54,55,57 Ras regulates survival and proliferation pathways, and
is constitutively activated in approximately 30% of all cancers with pancreas (90%), colon (50%)
and lung (30%) having the highest rates of aberrant Ras signaling.55 The most common
mutations of Ras are related to GAP insensitivity, which maintains Ras in an active GTP-bound
state. As GAP-based targeted therapies failed to impress, the downstream effectors of Ras have
grown as more suitable therapeutic targets.55,57
Raf serine/threonine kinases are direct downstream effectors of Ras. There are three
different forms of Raf (A-, B- and C- Raf) whose structures are similar, but differ considerably in
their modes of regulation, tissue distribution, and the ability to activate MAPK/ERK kinase
(MEK).54,63 B-Raf gets activated directly by Ras whereas A- and C-Raf require additional serineand tyrosine phosphorylation to become fully active.64 All three isoforms are able to
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phosphorylate MEK with B-raf being the strongest activator and A-Raf the weakest.63 B-Raf
mutations are quite prevalent in malignant melanomas (~66%) and many other cancers such as
colon and thyroid.54 The most common B-Raf active mutant form is B-RafV599E, which
constitutively induces ERK signaling.64
Activated Raf then phosphorylates MEK1/2 at two serine residues located on the kinase
domain, which in turn binds to and phosphorylates ERK1/2. Activated ERK1/2 can translocate to
the nucleus and induce genetic responses that regulate processes such as proliferation,
differentiation, survival, migration and angiogenesis.54-57 ERK1/2 can also modulate cell survival
through interaction with cytosolic substrates, most notably p90 ribosomal S6 kinase (p90RSK).
Activated p90RSK phosphorylates pro-apoptotic protein BAD resulting in its inactivation. It also
activates cAMP response element-binding protein (CREB), which translocates to the nucleus and
induces transcription of anti-apoptotic genes.65 Moreover, ERK1/2 can directly mediate
phosphorylation and proteasome-dependent degradation of pro-apoptotic protein BIM.66
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Figure 2. Ras/Raf/MAPK signaling pathway. Upon ligand binding, the tyrosine residues on
the kinase domain of EGFRs become transphosphorylated, which act as docking sites for the
adaptor protein GRB2. SOS binds to GRB2 and activates Ras by exchanging GDP for GTP.
GTP-bound Ras recruits Raf from cytosol to the membrane and activates it, which in turn
activates MEK1/2 by phosphorylating two distinct serine residues. Activated MEK1/2
subsequently activates ERK1/2, which translocates to the nucleus and induces multiple cellular
responses. ERK1/2 also interacts with cytosolic targets such as p90RSK and BIM leading to
activation of survival pathways.
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PI3K/AKT Pathway
When growth factors bind to the membrane receptor tyrosine kinases including EGFR,
PDGFR, or insulin-like growth factor 1 receptor (IGF1R), they induce receptor phosphorylation
and membrane recruitment of PI3K. PI3K is a lipid kinase that is comprised of two separate
subunits, a regulatory p85 and a catalytic p110, which heterodimerize upon activation. Activated
PI3K phosphorylates the lipid phosphatidylinositol 4,5-biphosphate (PIP2) generating the second
messenger phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 in turn recruits both
phosphatidylinositol-dependent protein kinase 1 (PDK1) and AKT to the membrane, where AKT
becomes phosphorylated on threonine 308 (T308) by PDK1 and additionally on serine 473
(S473) by the mechanistic target of rapamycin complex 2 (mTORC2) to become fully active
(Figure 3). Activated AKT induces survival, proliferation and growth through phosphorylation of
multiple downstream effectors. The PI3K/AKT pathway is negatively regulated by phosphatase
and tensin homolog (PTEN), a lipid phosphatase that dephosphorylates PIP3 to PIP2. 67-69
AKT promotes survival through interaction with multiple substrates. It directly blocks
activation of pro-apoptotic proteins BAD and pro-caspase 9. It also phosphorylates mouse
double minute chromosome 2 (MDM2). Phosphorylated MDM2 translocates to the nucleus
where it induces degradation of p53, an important tumor suppressor, through its E3 ubiquitin
ligase activity. In addition, AKT inhibits transcription factor forkhead box 1 (FOXO1), thus
blocking FOXO-mediated transcription of apoptotic factors.67-69
AKT also induces proliferation through inhibition of glycogen synthase kinase-3β (GSK3β) resulting in the accumulation of cyclin D1 and progression of cell cycle.67-69
Furthermore, AKT promotes protein synthesis and cell growth through activation of
mTOR complex 1 (mTORC1). In this process, AKT inhibits tuberous sclerosis complex 2
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(TSC2), which with its binding partner TSC1 act as a GAP for the Ras homolog enriched in
brain (Rheb) GTPase. Rheb strongly activates mTORC1 when it is in an active GTP-bound state.
Activated mTORC1 phosphorylates p70 S6 kinase (p70S6K) and eukaryotic initiation factor 4E
(eIF4E)-inhibitory binding protein (4EBP). Activation of p70S6K and eIF4E enhances mRNA
translation and increases protein synthesis.67-69 mTORC1 is also a major regulator of autophagy.
Under nutrient starvation, AMP activated protein kinase (AMPK) phosphorylates Unc-51 like
autophagy activating kinase 1 (ULK1) on serine residues 317 and 777, leading to initiation of
autophagy. Under nutrient sufficiency, mTORC1 phosphorylates ULK1 on serine 757, thus
disrupting the interaction between ULK1 and AMPK.70
Increasing evidence suggest that many cancers rely on activation of AKT and mTORC1
to drive tumorigenesis, and commonly deregulated status of this pathway has turned it into an
attractive target for therapeutic intervention. Activating mutations and gene amplification occur
at different levels in this pathway. For instance, loss-of-function mutations and complete loss of
PTEN is frequently observed in many cancers, including GBM, colon, breast, lung and
prostate.71 Gene amplification of p110 and AKT as well as activating mutations of p85 occur in
many cancers, including ovarian, breast and colon.72
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Figure 3. PI3K/AKT signaling pathway. The lipid kinase PI3K binds the kinase domain of the
EGFR receptor, and phosphorylates PIP2 to generate PIP3. PIP3 recruits both PDK1 and AKT to
the membrane where PDK1 phosphorylates AKT. Activated AKT induces protein synthesis and
survival through interaction with various substrates. mTOR, a major AKT target that acts as a
nutrient sensor, phosphorylates p70S6K and 4EBP. Released eIF4E and phospho-p70S6K
translocate to the nucleus and induce protein synthesis. This pathway is negatively regulated by
phosphatase PTEN, which dephosphorylates PIP3 to PIP2.
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JAK/STAT Signaling Pathway
The Janus family of kinases (JAKs) includes JAK1, JAK2, JAK3 and tyrosine kinase 2
(TYK2), which are involved in transduction of signals received from a variety of physiological
stimuli, including cytokines and growth factors. JAK1 is required in the signaling of proinflammatory cytokines such as interleukin (IL)-6, IL-1, and interferon-Ɣ (IFN-Ɣ). JAK2 is
important for hematopoietic growth factors, growth hormone and prolactin signaling. JAK3 plays
a role in mediating immune function whereas Tyk2 functions in part with JAK 2 and JAK3 to
transduce cytokine signaling. The function of JAK kinases are essential in cytokine signaling
since the members of the cytokine receptor superfamily lack intrinsic kinase activity.73,74
The signal transducers and activators of transcription (STAT) proteins are a family of
transcription factors that function downstream of JAKs. Seven members of the STAT family
have been identified so far (STAT1-4, STAT 5a, STAT 5b, and STAT6), which contain a SRC
homology 2 (SH2) domain, a DNA binding domain, and a transactivation domain.75-77
Upon cytokine binding and receptor dimerization, JAKs are recruited to the cytoplasmic
domains of the receptors where they phosphorylate specific tyrosine residues. Subsequently,
STATs bind these phosphorylated residues through their SH2 domains, and get tyrosine
phosphorylated on their transactivation domains by the JAKs. Once activated, STATs homo- or
heterodimerize through reciprocal phosphotyrosine-SH2 domain interactions. The dimmers then
translocate to the nucleus where they interact with other transcription modulators to induce gene
expression.73-76 Among the genes regulated by STATs are those coding for pro-survival proteins,
such as Bcl-2 family of proteins (e.g. Bcl-xL), those promoting cell proliferation, such as cyclin
D1, and those involved in angiogenesis and metastasis, such as VEGF (Figure 4).78
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JAK/STAT pathway is negatively regulated by two different families of proteins; the
suppressors of cytokine signaling (SOCS) proteins, and the protein inhibitors of activated STAT
(PIAS). SOCS proteins bind the phosphorylated residues on the cytokine receptors through their
SH2 domains. SOCS-1 has become known as a major tumor suppressor that directly binds JAK2
and inhibits JAK/STST signaling.77,79 The aberrant methylation of SOCS-1 gene has been
observed to a great extent in hepatocellular carcinoma, which shows the significance of
JAK/STAT signaling in tumor progression.80 The PIAS family includes PIAS1, PIAS3, PIASx
and PIASy. These proteins bind activated STAT dimmers and inhibit their function through
multiple different mechanisms.77,79
Constitutively activated STATs have been numerously reported in a variety of cancers
mainly due to deregulation of their upstream signaling proteins. STATs act as a point of
convergence for numerous upstream tyrosine kinases, and hold significant promise for the
development of new anti-cancer therapeutics. Many studies have indicated the role of STAT3
and STAT5 in oncogenesis, and their inhibition has been shown to be associated with tumor
suppression and cell death. In addition, activated STAT3 and STAT5 signaling has been
observed in breast, lung, and head and neck cancer mediated by increased cytokine signaling.75,77
Activation of STATs can also be caused by aberrant JAK signaling. A somatic gain-offunction mutation (V617F) in JAK2 is present in 50-60% of patients with primary myelofibrosis
and essential thrombocythemia. Amplification of JAK2 has also been implicated in 30-50% of
patients with Hodgkin lymphoma and primary B-cell lymphoma. Recently, targeted inhibition of
JAK2 generated promising results in patients with myelofibrosis leading to the approval of
ruxolitinib (Jakafi) by FDA in 2011.73,74
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Figure 4. JAK/STAT pathway. Upon cytokine binding and receptor dimerization, JAKs are
recruited to the receptor site where they phosphorylate tyrosine residues on the cytosolic domain
of the receptor. The phosphotyrosines act as docking sites for STATs to bind, and subsequently
get activated through phosphorylation by JAKs. Dimerized STATs translocate to the nucleus and
induce expression of genes involved in proliferation, differentiation and survival. This pathway
is negatively regulated by SOCS and PIAS family of proteins.
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Epidermal Growth Factor Receptor Tyrosine Kinase
The EGFR/ErbB family is a critical component in the autocrine growth regulation of
carcinoma, and is comprised of four different receptors; EGFR/ErbB1, ErbB2/HER2,
ErbB3/HER3, and ErbB4/HER4. All of these trans-membrane proteins are within the 170-190
kilo Dalton (kDa) size range and are composed of three different domains; the glycosylated
extracellular ligand-binding domain, a single hydrophobic trans-membrane domain, and an
intracellular catalytic domain.81,82 The hydrophobic domain anchors the receptor in the
membrane and connects the cysteine-rich growth factor binding extracellular domain to the
intracellular tyrosine kinase catalytic domain. Unlike ErbB1, 2 and 4 which are catalytically
active, ErbB3 does not have an active tyrosine kinase domain, but remains competent for ligand
binding and signal transduction. There is no known ligand that binds ErbB2, but ErbB2 remains
a favorite dimerization partner for the rest of the members.81,84
Ligand binding or receptor over-expression induces homo- or hetero-dimerization of
ErbB receptors, which results in trans-phosphorylation of tyrosine residues located on the
intracellular catalytic domain. The phospho-tyrosine residues on the cytoplasmic side of the
receptor act as docking sites for SH2 domain-containing signaling proteins that are involved in
activation of multiple downstream metabolic signaling cascades including PI3K/AKT,
Ras/Raf/MAPK and phospholipase C (PLC)/ protein kinase C (PKC).81,82 EGFR signaling also
activates STATs, which lately has been demonstrated to be mediated by Src family of kinases
(Figure 5).83
Aberrant ErbB signaling has been observed in a variety of cancers, and its activation has
been linked to invasion, metastasis, chemoresistance, and poor clinical outcome. Overexpression
of EGFR has been reported in many cancers, including 40-80% of NSCLC, 72-82% of colorectal
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cancer (CRC), and 50-90% of renal cell carcinoma. Amplification of HER-2 is present in 2530% of breast cancers. EGFR is also amplified in approximately 40-50% and over-expressed in
more than 60% of glioblastomas. Nearly 40% of the GBMs with EGFR amplification possess a
constitutively active mutant form of the receptor, EGFRvIII. Therefore, EGFR tyrosine kinases
have turned into one of the most sought after targets in cancer therapy.85,86
Two classes of EGFR inhibitors have been developed; monoclonal antibodies and
tyrosine kinase inhibitors (TKI). Monoclonal antibodies, such as trastuzumab and cetuximab,
bind to the extracellular domain of the receptor, and prevent ligand binding whereas TKIs, such
as erlotinib and lapatinib, block the ATP binding pocket of the receptors, thus blocking receptor
activation.82,85 In spite of the initial positive results, a variety of mechanisms of acquired
resistance have been observed in response to targeted EGFR therapeutics, which have drastically
lowered their success rates. The occurrence of secondary mutations, activation of parallel
tyrosine kinase signaling pathways, and loss of tumor suppressors, such as PTEN are just a few
examples of drug resistance mechanisms frequently counteracting EGFR inhibition-based
therapies. Therefore, there is growing evidence that the combination of EGFR inhibitors with
chemotherapy or other signal-transduction inhibitors will create a more potent therapy.82
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Figure 5. EGFR signaling. Ligand binding induces trans-phosphorylation of tyrosine residues
located on the intracellular catalytic domain. The phospho-tyrosine residues on the cytoplasmic
side of the receptor act as docking sites for SH2 domain-containing signaling proteins that are
involved in activation of multiple downstream metabolic signaling cascades, including
PI3K/AKT, Ras/Raf/MAPK and PLC/PKC. STATs also get activated in a Src-mediated fashion.
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Nitric Oxide Signaling
Nitric oxide (NO) is a small uncharged highly diffusible gaseous molecule that plays a
critical role in regulation of cardiovascular and immune system. NO is generated through the
catalytic activity of NO synthases (NOS), which convert L-arginine and molecular oxygen to Lcitrulline and NO.87,88 NOS activity depends on several cofactors, including NADPH and
tetrahydrobiopterin (BH4). BH4 plays a critical role in NOS activity. Small ratio of BH4 relative
to its oxidized form, dihydrobiopterin (BH2), causes NOS uncoupling, leading to production of
reactive oxygen species (ROS) and reactive nitrogen species (RNS) rather than NO. Uncoupling
of NOS results in a decrease in vascular NO level, which commonly occurs during aging,
inflammatory diseases, cardiovascular diseases and cancer.87,89 There are three isoforms of NOS:
the inducible NOS (iNOS) that functions in inflammatory response, the endothelial NOS (eNOS)
that generates NO as a paracrine signal in the vascular system, and the neuronal NOS (nNOS)
that produces NO that acts as a neurotransmitter in the nervous system.87,88
Shear stress generated by streaming blood is sensed by the endothelial cells through
activation of PI3K/AKT pathway. AKT phosphorylates eNOS, leading to its catalytic activation
and generation of NO.90 Soluble guanylate cyclase (sGC) is the primary target of NO, which
converts GTP to cyclic GMP (cGMP) upon activation. cGMP-dependent protein kinase G (PKG)
is a major recipient of cGMP , which phosphorylates numerous targets, resulting in diverse
physiological responses including vasodilatation and angiogenesis.87,88 Phosphodiesterases
(PDE) are a family of enzymes that hydrolyze cAMP and cGMP to their inactive forms 5’-AMP
and 5’-GMP, respectively (Figure 6). PDE5 inhibitors, such as sildenafil (Viagra), increase NO
signaling by preventing the cGMP breakdown, and are currently approved for the treatment of
erectile dysfunction and pulmonary arterial hypertension.87,88
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Figure 6. NO signaling in the vascular system. The endothelial cells sense the shear stress
from the streaming blood, leading to the activation of PI3K/AKT pathway. Activated AKT
phosphorylates eNOS and induces NO generation into the adjacent connective tissue. The
Soluble GC in the smooth muscle cells is the major target of NO. Activated sGC converts GTP
to cGMP, which acts as an important secondary messenger. PKG is a major recipient of cGMP
that phosphorylates numerous targets, resulting in diverse physiological responses including
vasodilatation. This cycle is negatively regulated by PDEs that break down the cGMP to its
inactive 5’-GMP form.
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Apoptosis: Intrinsic and Extrinsic Pathways
Apoptosis, also referred to as programmed cell death type I (PCDI), is an energydependent multi-step biochemical process that plays a crucial role in tissue homeostasis in
multicellular organisms, and its deregulation contributes to many diseases, including cancer,
autoimmunity and AIDS. Morphologically, apoptosis is characterized by membrane blebbing,
cell shrinkage, nucleus fragmentation, chromatin condensation and DNA degradation.91-93 There
are two distinct apoptotic pathways: the extrinsic or death receptor pathway and the intrinsic or
mitochondrial pathway. However, new evidence suggested that these two pathways are
connected and the components of one pathway can influence the other.91 Both extrinsic and
intrinsic pathways converge on the activation of specific intracellular poteases, the caspase
family. Caspases are intracellular cysteine proteases that cleave proteins next to aspartate
residues. Caspases, typically categorized into initiators and executioners, are synthesized as
inactive zymogens and become activated upon cleavage by their upstream modulators.91,94
Caspase 3 is the most important of the executioner caspases, and is activated by any of the
initiator caspase 8, 9 and 10 in both extrinsic and intrinsic pathways. Executioner caspases
(caspase 3, 6 and 7) cleave various substrates including cytoskeletal and nuclear proteins, and
also activate other proteases and endonucleases involved in protein degradation and DNA
fragmentation.91,94
Unlike the extrinsic pathway that is mediated by death receptors, the intrinsic pathway is
strictly controlled by the B-cell lymphoma-2 (Bcl-2) family of proteins.91,94 The Bcl-2 family
consists of three different classes: the anti-apoptotic group I, the pro-apoptotic group II and
group III proteins that bind and regulate the activity of anti-apoptotic group II proteins. Group I
family members such as Bcl-2, Bcl-x long (Bcl-xL) and myeloid cell leukaemia-1 (Mcl-1)
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directly bind and inhibit pro-apoptotic group II family members including Bcl-2-associated X
protein (BAX) and Bcl-2 homologous antagonist/killer (BAK). Whereas, the group III family
members, commonly referred to as Bcl-2 homology (BH) 3-only proteins, including p53
unregulated modulator of apoptosis (PUMA), NADPH oxidase activator (NOXA), BH3
interacting domain death agonist (BID) and Bcl-2 interacting mediator of cell death (BIM) either
directly or indirectly interact with pro-apoptotic group II family members and induce their
insertion in the mitochondrial membrane.91,94 The indirect activation of BAX and BAK by BH3only proteins seems to be more validated since recent studies concluded that BAK can only
induce cell death if it is displaced from prosurvival proteins Mcl-1 and Bcl-xL through BAD and
NOXA.95 Further studies demonstrated a role for the tumor suppressor p53 in synthesis of
PUMA and NOXA, linking DNA damage to apoptotic cell death.96,97
The intrinsic pathway is activated by various stimuli such as viral infection, DNA
damage and absence of certain growth factors, hormones and cytokines. After exposure to these
stimuli, BAX and BAK homo-oligomerizae in the outer membrane of mitochondria leading to
mitochondrial membrane permeabilization, formation of pores, and release of cytochrome-c and
other pro-apoptotic proteins, such as caspase-activated deoxyribonuclease (CAD), apoptosisinducing factor (AIF) and endonuclease G, from the inter-membrane space into the cytosol.91,94
In the cytosol, cytochrome-c binds apoptotic protease-activating factor-1 (Apaf-1), which in turn
binds pro-caspase 9 to form a complex known as the apoptosome. Binding to Apaf-1 induces
conformational change and activation of caspase 9, which proteolytically activates executioner
caspase 3.91,94 Besides its proteolytic activity in the cytosol, cleaved caspase 3 can also activate
caspase 6, another executioner caspase, and CAD by cleaving its inhibitor (ICAD). CAD
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alongside AIF and endonuclease G, which unlike CAD function in a caspase-independent
manner, translocate to the nucleus where they lead to DNA fragmentation.91,93,94
The extrinsic signaling pathway is activated when death receptors bind their natural
ligands from the tumor necrosis factor (TNF) family. These death receptors, which belong to the
TNF receptor family, consist of a cysteine-rich extracellular domain for ligand binding and a
cytoplasmic domain of 80 amino acids called the death domain (DD) involved in signal
transduction.91-93 The best-characterized member of this family is Fas receptor, also known as
cluster of differentiation 95 (CD95). The Fas receptor is a 45-kDa trans-membrane protein that
binds to its ligand (FasL) through its cysteine-rich extracellular domain. Ligand binding induces
conformational changes in the receptor structure that allows Fas to recruit an adaptor protein
called Fas-associated death domain (FADD). FADD contains another important motif, the deatheffector domain (DED) that binds initiator caspases 8 and 10 through complementary DED
domains. This death-inducing signaling complex (DISC) leads to auto-proteolytic cleavage and
activation of caspases 8 and 10, which subsequently activate executioner caspases 3 and 7 to
induce apoptotic response (Figure 7).91-93 The extrinsic pathway may also result in the release of
cytochrome-c and the induction of the intrinsic pathway through activation of BID that serves as
a substrate for caspase 8. Upon activation at the DISC, truncated BID (tBID) translocates to the
mitochondria and induces the release of apoptotic proteins from the intermembrane space into
the cytosol.91,98 The extrinsic apoptotic pathway is regulated at early stage by FLICE-inhibitory
proteins (FLIP), which bind to the DISC and inhibit activation of caspase 8.92,93
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Figure 7. Intrinsic and extrinsic apoptotic pathways. The intrinsic pathway is controlled by
Bcl-2 family of proteins that induce release of cytochrome c from the intermembrane space of
mitochondria into the cytosol. Cytochrome c causes Apaf-1 to bind and activate initiator caspase
9. Cleaved caspase 9 then activates executioner caspase 3. On the other hand, the extrinsic
pathway is initiated by binding of TNFs to the TNFRs. The TNFRs then recruit adaptor protein
that can bind and activate initiator caspases 8 and 10. These initiator caspases in turn activate
caspases 3 and 7. Caspase 8 can also activate BID, which can translocate to the mitochondria and
induce release of cytochrome c.
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Deregulation of Apoptosis in Cancer
Deregulation of apoptosis plays a critical role in the development of cancer and drug
resistance.2,99 Apoptosis is highly regulated through the interplay between the proapoptotic and
antiapoptotic Bcl-2 family of proteins. Numerous studies have pointed at the oncogenic
capability of proapoptotic Bcl-2 family members.95 A study by Amundson et al100 demonstrated
a strong correlation between the expression level of Bcl-xL and resistance to chemotherapy.
Alternatively, based upon the loss-of-function mutagenic studies, it has been rightfully argued
that antiapoptotic proteins act as tumor suppressors.95 In support of this claim, studies indicated
that the BIM gene underwent biallelic deletion and promoter hypermethylation in majority of
mantle cell and Burkitt lymphomas, respectively.101,102 The tumor suppressor activity of
antiapoptotic proteins is further supported by the increasing evidence that BH3-only proteins get
activated in response to anticancer drugs.95 For example, it has been suggested that Gleevec
induces apoptosis through activation of BIM and BAD.103 Another study by Tan et al104 showed
that paclitaxel induced BIM-dependent apoptosis, which was abrogated by activation of Ras and
subsequent degradation of BIM in proteasomes. They also argued the potentials benefit of the
proteasome inhibitor Velcade and paclitaxel combination in the treatment of epithelial tumors.
p53 is another regulator of apoptosis that induces cell death in response to DNA breaks,
hypoxia and proliferative signals.2,99 TP53 is the most commonly mutated gene in cancer cells,
and studies have established a strong correlation between the wild type p53 status and the
response to anticancer agents.105 p-53-mediated apoptosis is primarily linked to an increase in the
transcription of PUMA and NOXA, two BH3-only proteins that interact with antiapoptotic Bcl-2
family members.95-97 Collectively, these findings articulate the significance of Bcl-2 family of
proteins in regulating apoptosis in cancer, which can be exploited as targets in future therapies.
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Autophagy
Autophagy is an evolutionary conserved degradative mechanism that is required for
maintaining cellular homeostasis by recycling and turnover of cytoplasmic components.
Autophagy is associated with various physiological and pathological processes including
development, aging, cancer, neurodegenerative disorders and infectious diseases.106-108 Cancer
therapeutics also have the ability to induce autophagy predominantly through interruption of
EGFR pathway, activation of MAPK signaling pathways and induction of ER stress.107
Autophagy occurs in three different modes: macroautophagy, microautophagy and
chaperone-mediated autophagy. Macroautophagy (hereafter referred to as autophagy) is the main
lysosomal rout for recycling long-lived macromolecules and also organelles, such as
mitochondria and peroxisomes, when damaged or in excess. It is characterized by formation of
double-membrane vesicles named autophagosomes around targeted cellular components, which
directly fuse with lysosomes for enzymatic degradation. Microautophagy involves direct
engulfment of cytoplasmic components into the lysosome through invagination of the lysosomal
membrane, whereas chaperone-mediated autophagy is the selective degradation of cytoplasmic
proteins, which contain a specific motif that can be recognized by lysosomal receptors.106-108
Out of 31 autophagy-related genes (ATG) discovered by yeast genetic studies, 18 genes
are involved in autophagosome formation. Since autophagy is an evolutionary conserved
process, most of these genes have mammalian homologs with similar functionality.108,109
Mammalian ATG9 is a trans-membrane protein essential for autophagosome formation
that has localizes to the trans-Golgi Network (TGN). Upon starvation, BAX-interacting factor-1
(Bif-1) co-localizes with ATG9 and induces fragmentation of Golgi. The ATG9-containing
fragments are dispersed in the cytosol and are utilized for autophagosome formation.108 This
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process requires activation of classIII PI3K (PI3KC3) complex, which consists of PI3KC3, p150,
Beclin-1, ultraviolet radiation resistance-associated gene (UVRAG) and ATG14L that acts
upstream of ATG9 trafficking. PI3KC3 forms a complex with p150 adaptor that tethers the
enzyme to the cytoplasmic membrane. PI3KC3 then binds Beclin-1 that serves as a binding
partner for UVRAG and ATG14L. Bif-1 binds the complex by interacting with UVRAG.
Activation of PI3KC3 complex II is regulated by mTOR signaling and is crucial for ATG9
trafficking and initiation of autophagosome formation.108-110 AMPK and mTORC1 are major
regulators of autophagy. Under nutrient starvation, AMPK phosphorylates ULK1 on serine
residues 317 and 777, leading to initiation of autophagy. Under nutrient sufficiency, mTORC1
phosphorylates ULK1 on serine 757, thus disrupting the interaction between ULK1 and
AMPK.70 Activated ULK1 is recruited by ATG14L to directly phosphorylate Beclin-1 and
induce activation of PI3KC3. Activated PI3KC3 phosphorylates phosphatidylinositol (PI) to
produce phosphatidylinositol 3-phosphate (PI3P) that serves as an anchor for PI3P-binding
proteins such as ATG18 to bind to form phagophores.110 Recent studies have shown that there
are two different PI3KC3 complexes: complex I contains PI3KC3, p150, Beclin-1 and ATG14L
whereas in complex II ATG14L is replaced by UVRAG. Complex I is involved in Formation of
phagophores while complex II contributes to autophagosome maturation.109,110 The crescentshaped phagophores, also known as isolation membranes, are extended to form doublemembrane autophagosomes in a process that involves two ubiquitin-like (UBL) conjugation
systems. These UBL systems function in a manner that resembles the ubiquitylation process
involved in protein degradation, which is composed of a ubiquitin-activating enzyme (E1), a
ubiquitin-conjugating enzyme (E2) and a ubiquitin-protein ligase enzyme (E3).106,111 In the first
UBL system, ATG12 is activated by E1-like enzyme ATG7, forming an ATG12-ATG7 thioester
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intermediate before being transferred to ATG10, an E2-like enzyme. In the last step ATG12
covalently binds ATG5, and ATG12-ATG5 conjugate non-covalently interacts with ATG16L to
form the final complex. This complex dissociates from the membrane when autophaosome
formation process is complete. The second UBL system involves modification and incorporation
of microtubule-associated Protein 1 Light Chain 3 (LC3) into the autophagosome membrane.
The C-terminal region of LC3 is first cleaved by ATG4 to form LC3-I. E1-like enzyme, ATG7,
activates LC3-I, which is then transferred to ATG3, an E2 like enzyme. In the final step, LC3-I is
covalently bound to phosphatidylethanolamine (PE) to form the lipid-protein conjugate LC3-II
(Figure 8). LC3-II is tightly associated with autophagosomes, and can be used as an autophagic
marker in mammalian cells. Upon formation, autophagosomes are fused with lysosomes to
complete protein degradation.106,111
In addition to bulk degradation of cytoplasmic macromolecules and excessive organelles
as a result of nutrient deprivation, autophagy can also take part in degradation of mis-folded
proteins. This process is mediated by the adaptor molecule p62 (sequestosome 1), which
possesses specific domains to bind both the ubiquitin moiety on the poly-ubiquitinated misfolded
proteins and the LC3 on the autophagosome membranes. Lysosomal degradation of
autophagosomes results in a decrease in p62 levels, which makes p62 a suitable marker for
tracking autophagy in mammalian cells.112
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Figure 8. Autophagosome formation in mammalian cells. AMPK gets activated in response to
amino acid starvation, and phosphorylates ULK1. Activated ULK1 subsequently binds ATG14L
to phosphorylate Beclin-1. Phosphorylation of Beclin 1 activates PI3KC3 in complex I leading to
production of PIP3 that in turn induces nucleation. Autophagosome formation requires two UBL
conjugation systems. UBL system 1 produces ATG5-ATG12-ATG16L1 conjugates that attach
the isolation membranes and facilitate membrane nucleation. UBL system 2 modifies LC3 and
incorporates the final product, LC3-II, into the autophagosome membrane. The final step in this
process is fusion of the lysosomes with the autophagosomes that leads to complete degradation
of autophagosome contents.
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The Role of Autophagy in Cancer
The role of autophagy in cancer resembles a double-edged sword; acting as a
cytoprotective as well as a cytotoxic mechanism.2,113 Radiotherapy and many anticancer drugs
induce autophagy that seemingly impairs cell death.113 However, quite contrary to its protective
nature, there is increasing evidence that autophagy acts as a tumor suppressor.113,114 Monoallelic
loss of beclin1 gene has been shown to promote tumorigenesis associated with chromosomal
instability and gene amplification, suggesting Beclin1 as a tumor suppressor.115 Another study
demonstrated that breast cancer cell lines frequently possessed allelic deletion of beclin1gene.116
Moreover, exogenous expression of Beclin1 in MCF7 cells, which lack the endogenous Beclin1
expression, inhibited tumorigenesis.114 Beclin1, a necessary regulator of autophagy, is a novel
BH3-only protein, which provides a crosstalk point between autophagy and apoptosis.
Antiapoptotic proteins Bcl-2 and Bcl-xL can bind to Beclin1 and inhibit autophagy whereas
other proapoptotic BH3-only proteins such as BID, BAD and PUMA can displace Beclin1, and
induce apoptosis and/or autophagy.2,117
Autophagy and apoptosis can also crosstalk through of mTOR. Activation of the prosurvival AKT/mTOR pathway blocks apoptosis as well as autophagy through inactivation of
ULK1. A role of activated PI3K/AKT/mTOR signaling, which is a common characteristic of
many cancer cells, in the negative regulation of autophagy provides more evidence for the role of
autophagy in tumor suppression.2,114
Perhaps, the formation of autophagic vesicles in the drug-treated cancer cells could
initially be a cytoprotective mechanism to degrade the damaged organelles. However, after a
certain degree of damage, autophagy might induce activation of cell death. Nevertheless,
whether cells are ultimately destroyed by cytotoxic autophagy requires more investigation.114
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Endoplasmic Reticulum Stress
Proteins targeted for secretory pathway are folded in the lumen of endoplasmic reticulum
(ER) by chaperones before being transported to Golgi apparatus for final modification and
secretion. Interruption in this process results in accumulation of unfolded proteins in the lumen
of ER, referred to as ER stress, and induction of the unfolded protein response (UPR). The UPR
is a series of actions that collectively reduce the rate of protein synthesis and activate
transcription factors that enhance function of the ER.118-120 There are three transmembrane
proteins in the membrane of ER that sense the accumulation of misfolded proteins and trigger the
UPR: PKR-like eukaryotic initiation factor 2α kinase (PERK), inositol requiring enzyme 1
(IRE1) and activating transcription factor-6 (ATF6). This sensory mechanism is mediated by the
chaperone protein glucose-regulated protein of 78 kDa (GRP78), also known as binding
immunoglobulin protein (BiP), present in the lumen of the ER. Under normal conditions, GRP78
is bound to the luminal domains of PERK, IRE1 and ATF6 inhibiting their function. Upon ER
stress occurrence, GRP78 is released to bind to the unfolded protein leading to the activation of
the three stress sensors. Upon activation, ATF6 is proteolytically cleaved and directly
translocated into the nucleus to induce the expression of the genes required for the UPR.
However, activation of PERK and IRE1 is associated with dimerization and subsequent
autophosphorylation of specific residues on their cytoplasmic kinase domains.118-120 Activated
IRE1, induces formation of the transcription activator spliced X-box binding protein (XBP-1)
through splicing of the XBP-1 messenger RNA whereas PERK phosphorylates the α subunit of
eukaryotic initiation factor 2 (eIF2α) (Figure 9). Normally, GTP-bound eIF2 binds to methionyltransfer RNA and enhances recognition of start codon and is released from ribosomal machinery
when GTP is hydrolyzed. Phosphorylation of the α subunit of eIF2 inhibits the exchange of GDP
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for GTP; thus, reducing protein synthesis. Furthermore, activated PERK translationally controls
the expression of activating transcription factor 4 (ATF4) that induces the expression of variable
UPR-related genes involved in amino acid metabolism, regulation of oxidative stress and
apoptosis.119
To prevent aggregation of misfolded proteins in the lumen of ER during ER stress, XBP1
and ATF6 increase expression of proteins that facilitate ER-associated degradation (ERAD).
ERAD is accomplished by retrotranslocation of misfolded proteins into the cytosol followed by
ubiquitination and proteasomal degradation. ER stress can also induce autophagy as an alternate
route for protein degradation.118 The exact mechanism of ER stress-induced autophagy and its
probable cytoprotective function is not very well elucidated yet, but as previously stated, this
process is highly regulated by p62, which has the proper domains to bind the ubiquitin moiety of
the misfolded proteins as well as the LC3 on the autophagosomes.112
Severe ER stress can also induce apoptosis, through a process mediated by the interplay
between Bcl-2 proteins and the UPR components. C/EBP homologous protein (CHOP) is a
transcription factor that is induced by all three arms of the UPR that can regulate the expression
of Bcl-2 proteins.120 There is also evidence that CHOP can directly interact and activate certain
BH3-only proteins such as BIM, thereby directly promoting apoptosis.121 Moreover, It has been
suggested that ER stress-induced apoptosis occurs through cleavage of caspase 4, a member of
caspase 1 subfamily that localizes to the ER membrane.121
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Figure 9. The mechanism of unfolded protein response. Upon accumulation of unfolded
proteins in the lumen of the ER, the chaperone GRP78 (BiP) is released from the luminal
domains of PERK, ATF6 and IRE1. These activated transmembrane proteins then trigger
cascades of events that collectively result in expression of UPR-related genes. Severe ER stress
can also induce apoptosis through CHOP-mediated changes in the expression of Bcl-2 proteins,
direct activation of BH3-only proteins by CHOP, or cleavage of ER membrane-bound caspase 4.
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ER Stress in Cancer
The high proliferative and metabolic rates in cancer cells lead to a tumor
microenvironment characterized by glucose limitation, acidosis, and hypoxia. These conditions
can result in accumulation of misfolded proteins and induction of UPR.123,124 In fact, an
increased expression of GRP78 and GRP94 have been observed in many different cancers,
including cancers of breast, colon and liver. Both of these chaperones have been shown to play a
role in resisting cell death.124,125 In the same cancers, elevated level of GRP78 has also been
linked to high pathologic grade, greater risk of recurrence, and poor survival.123 Moreover,
GRP78 has been shown to confer resistance to chemotherapeutics in multiple tumor type, and its
knockdown has been demonstrated to sensitize the glioma cells to TMZ.123 Furthermore, In
support of the role of GRP78 in cancer, studies have indicated that heterozygous GRP78 mice
had impaired tumor progression, reduced tumor sized and a longer latency period.123,125 In
addition, other studies have suggested the involvement of ER stress in the induction of
angiogenesis and metastasis through upregulation of VEGF-A.123,124 This claim is further
supported by studies in xenograft models where knockdown of GRP78 was associated with less
invasion and metastasis.123 Surprisingly, GRP78 has also been detected on the surface of highly
metastatic prostate cancer cells, further supporting its probable function in tumor progression and
metastasis. The surface GRP78 provides a suitable, more accessible target that can be potentially
utilized in combination therapies.123 Recent studies from our laboratory have indicated that
targeting GRP78 is of therapeutic utility for cancer and also for the treatment of bacterial and
viral infections.126 Collectively, these findings suggest that GRP78 can serve as a potential
therapeutic target in cancer as well as a novel biomarker to enhance patient treatment in the
future.123
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CHAPTER 2: Materials and Methods
Materials
All drugs were purchased from Selleckchem (Houston, TX). Cell lines were obtained from
ATCC (Bethesda, MD) and were not further validated beyond the validation statements of the
provider. All media for cell culture (DMEM, RPMI, MEM Alpha, F-12 and Opti-MEM), trypsinEDTA, penicillin-streptomycin and 1X Phosphate-buffered saline solution (PBS) were all
purchased from GIBCOBRL (Invitrogen-GIBCOBRL Life Technologies, Grand Island, NY).
Fetal bovine serum (FBS) was purchased from HyClone Laboratories, Inc (Thermo Scientific
Hyclone, South Logan, UT). Bovine serum albumin (BSA), sodium dodecyl sulfate (SDS) and
glycine were purchased from Fisher Scientific (Fair Lawn, NJ). Trypan blue solution,
formaldehyde, 6-Diamidino-2-Phenylidole (DAPI), dimethyl sulfoxide (DMSO), rat serum,
RIPA buffer, bovine insulin, hydrocortisone, crystal violet stain and McCoy’s 5A Medium
Modified were all obtained from Sigma-Aldrich (St. Louis, MO). Chaps cell extract buffer (10X)
was obtained from Cell Signaling Technology (Danvers, MA). Anti-Bak, NT polyclonal and
anti-Bax (active monomer, mAb, 6A7) antibodies were purchased from EMD Millipore
(Temecula, CA) and Enzo Life Sciences (Farmingdale, NY), respectively. All other primary
phospho-/total-antibodies were purchased from Cell Signaling Technology (Danvers, MA),
Santa Cruz Biotechnology (Santa Cruz, CA) and Abcam (Cambridge, MA). Secondary
antibodies (IRDye 680LT Goat anti-Mouse and IRDye 800CW Goat anti-Rabbit) and Odyssey
infrared imaging system blocking buffer were obtained from LI-COR Biosciences (Lincoln, NE).
Alexa Fluor 680 goat anti-mouse IgG, Alexa Fluor 594 goat anti-rabbit IgG, ethidium
homodimer-1 and calcein-AM were obtained from Life Technologies (Carlsbad, CA). Validated
siRNAs were purchased from QIAGEN (Valencia, CA). Recombinant adenoviruses to express
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constitutively activated c-FLIP-s and Bcl-xL and dominant negative caspase 9 were purchased
from Vector Biolabs, (Philadelphia, PA). Dr. S. Spiegel (VCU) kindly supplied the plasmid to
express green fluorescent protein-tagged (GFP) human LC3 for vesicle formation assay. All
other plasmids were obtained from Addgene (Cambridge, MA). The JNK Inhibitor VII, TAT-TIJIP was purchased from Calbiochem (EMD Chemicals, Inc. San Diego, CA). All western
blotting equipments were purchased from BIO-RAD (Hercules, CA).
Methods
Cell Culture
HUH7, HEPG2, HEP3B and HT29 cells were cultured in DMEM supplemented with 5%
(vol/vol) FBS. HT1080 cells cultured in MEM supplemented with 10% (vol/vol) FBS. HCC38,
BT474, MCF7 and BT549 cells were cultured in RPMI supplemented with 10% (vol/vol) FBS.
HCT116, MES-SA, Saos-2 and SKES-1 were cultured in McCoy’s 5a Medium Modified
supplemented with 10% (vol/vol) FBS. SUM149PT cells were cultured in Ham’s F-12 medium
supplemented with 5% (vol/vol) FBS, 0.5% (vol/vol) bovine insulin and 0.1% (vol/vol)
hydrocortisone. All media used in cell culture were also supplemented with 100 µg/ml (1%
vol/vol) penicillin/streptomycin. Cells were incubated in a humidified atmosphere of 5% CO2 at
37 °C. For cell viability assays and immunoblotting/immunofluorescence, cells were plated at a
density of 2 × 104 (per well of a 12-well plate) or 5 × 103 (per well of a 96-well plate) for 24-30
hours prior to any treatment.
Drug Treatment
Plated cells were treated with desired drugs, which were taken from a 10mM stock
solution and diluted in DMSO to reach the desired concentration. The maximal concentration of
vehicle (DMSO) in media was 0.02% (v/v).
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Assessment of Cell Viability
For trypan blue exclusion assays in 12-well plates, the media from each well was
transferred into a 15ml tube. Attached cells were harvested by trypsinization with trypsin/EDTA
for 5 minutes at 37°C and then transferred into the corresponding tube. After centrifugation at
1,200 rpm for 5 minutes the supernatant was removed and the pellet was re-suspended and mixed
with the vital stain trypan blue. Insertion of trypan blue stain into the cell cytoplasm was used as
an indicator of cell death. A total of 500 cells from randomly selected fields per experimental
point were counted using a hemocytometer and a light microscope. The percentage of dead cells
was expressed as a percentage of the total number of cells counted.
For live/dead imaging assays in 96-well plates, 100 μL aliquots of 1X PBS containing
1:2000 dilutions of red fluorescent ethidium homodimer-1 (to detect cells with disrupted cell
membranes) and green fluorescent calcein-AM (to indicate intracellular esterase activity) was
added to each well and plates were spun at 800 rpm for 3 minutes to sediment detached dead
cells onto the plate. Cells were then visualized using a Hermes Wiscan instrument (IDEA BioMedical, Rehovot, Israel) under 10X magnification. The number of viable (green) and dead (red)
cells were counted manually from several images taken from each well. All viability assays were
performed in triplicates.
Western Blot Analysis
Cells were plated in 60 x 15mm dishes for 24 hours prior to treatment. They were treated
with the desired concentration of drugs and were incubated for 3, 6, 12 or 24 hours. After
incubation, cells were lysed and scraped using whole-cell lysis buffer (0.5 M Tris-HCl, pH 6.8,
2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol, 0.02% (w/v) bromophenol
blue). Collected samples were boiled for 10 minutes and then loaded onto 8-14% sodium
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dodecyl sulfate–polyacrylamide gel (SDS-PAGE). Proteins were electrophoretically separated
and transferred onto 0.45 µm PVDF membrane. The membrane was blocked in Odyssey
blocking buffer. The membrane was then exposed to desired primary antibodies overnight. After
removal of the primary antibody, the membrane was then incubated with the corresponding goat
anti-mouse or rabbit secondary antibody for 2 hours at room temperature. After being washed
three times with TBST, the immunoblots were visualized using an Odyssey Infrared Imager (LICOR Biosciences, Lincoln, NE).
Infection with Adenovirus
Cells were plated in 12-well. 24 hours later the media was removed and replaced by 1ml
of plain medium (lacking FBS and penicillin-streptomycin). Recombinant adenoviruses to
express constitutively activate c-FLIP-s, Bcl-xL and dominant negative caspase 9 or empty
vector virus were added at a multiplicity of infection (MOI) of 50. In case of infection in 96-well
plates, the plain medium containing the adenoviruses was prepared in 1.5 mL-eppendorf tubes
and then distributed in 100 µL portions into the corresponding wells. The plates were incubated
for 6 hours and then the plain media was replaced by serum-containing medium (supplemented
by FBS and penicillin-steptomycin). The cells were then incubated for 24 hours to ensure
adequate expression of transduced gene products prior to drug exposures.
Plasmid and siRNA Transfection
For transfection, 0.5 µg of each plasmid was diluted into 50 µl of Opti-MEM medium
with no added serum or antibiotic and was incubated in solution for 5 minutes at room
temperature. Concurrently, 1 µl of Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) was
diluted into 50 µl of the same medium and was given the same incubation time. After 5 minutes,
the two solutions were mixed together and incubated at room temperature for 20 minutes. The
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total mix was added to each well containing 400 µl of the same serum/antibiotic free medium.
Cells were incubated for 4 hours before equal volume (500 µl) of the appropriate medium
containing twice the volume of required FBS was added to each well. Cells were then incubated
for 24 hours before being exposed to desired drugs.
Transfection with validated siRNAs was performed in a similar fashion to plasmids with
all specified siRNAs used at 10nM concentration of the annealed siRNA or the negative control
(a “scrambled” sequence with no homology to any known genes in human or mouse cell lines).
Protein Analysis by Immunofluorescence Imaging
Cells plated in 96 well plates were treated with desired drugs for certain amount of time
and were then washed with 1X PBS and fixed in 4% paraformaldehyde for 15 minutes. Fixated
cells were then blocked with 0.5% triton-X-100 PBS solution supplemented with 10% rat serum
for 1-2 hours followed by an overnight exposure to 1:500 solution of desired primary antibodies.
Cells were then washed with PBS and incubated with a 1:2000 dilution of appropriate secondary
Alexa Fluor anti-mouse or anti-rabbit for 2-4 hours. Fluorescent signals were detected using a
Hermes Wiscan instrument (IDEA Bio-Medical, Rehovot, Israel).
LC3-GFP Vesicle Formation Assay
Cells were plated in 4-well glass slides and were transfected with the LC3-GFP plasmid.
24 hours after transfection, cells were treated with the indicated drugs and were visualized on a
ZeissAxiovert 200 micoscope (Carl Zeiss, Wake Forest, NC) 6 and 12 hours after the treatment.
The number of vesicles in 40 cells representing each group was counted, and the average vesicles
formed in each group was calculated. Colocalization of LC3 to the lysosomal and the
mitochondrial membranes was assessed using LysoTracker Red DND-99 (Life Technologies,
#L7528) and MitoTracker Red CMXRos (Life Technologies, #M7512), respectively. 24 hours
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after drug exposure, the medium was removed and the cells were incubated with plain medium
(no serum added) containing 25nM of either LysoTracker or MitoTracker probe for 30 minutes
before being subjected to fluorescent microscopy as previously described.
Tumor Cell Isolation
Tumor dissociation was performed using a GentleMACS Dissociator purchased from
Miltenyi Biotec (San Diego, CA) and was carried out according to the manufacturer’s
recommended protocol. In short, extracted tumors were cut into small pieces of 2-4 mm and
were put in a compatible GentleMACS tube with the recommended enzyme mixture. The
samples were mixed and homogenized by GentleMACS Dissociator and were incubated for 30
minutes at 37ºC under continuous rotation. After a short centrifugation at 1500 rpm, cells were
re-suspended and applied to a strainer 30-70 µm (based on cell size). Cells were then grown in
appropriate cell medium.
In Vitro and Ex Vivo Colony Formation Assay
250-1000 cells/well were seeded in a 6-well plate. A day later, cells were treated with
appropriate drugs for 24 hours before the drug-containing medium was aspirated and replaced by
fresh medium. The cells were then cultured for up to two weeks until colonies were observed in
the control group. The medium was then removed and cells were washed with 1X PBS. The cells
were then fixed in 100% methanol for 10 minutes. After methanol removal, 0.1% (vol/vol)
crystal violet stain was added to each well for at least 1 hour. Wells were the washed and number
of colonies was counted manually.
For ex vivo colony formation assay, the tumors were harvested from the nude mice at the
time of sacrifice and were isolated (as previously described) to obtain a single cell suspension.
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Cells were then plated 100-10000/well of a 6-well plate. Colonies were permitted to form for 710 days and were fixed, stained and counted.
Analysis of ROS and RNS Levels
Cells were plated into a 96-well plate at a density of 10,000 cells/well. 24 hours later,
cells were incubated with 2’,7’-Dichlorofluorescin diacetate (Sigma, #122M4000V)

at a

concentration of 10 µM, or 3-Amino-4-(N-methylamino)-2', 7'-difluorofluorescein diacetate
(DAF-FM DA) at a concentration of 4 µM for 30 minutes. The DCF-containing medium was
then removed and cells were washed with 1X PBS before 100 µL of fresh medium containing
desired drugs was added to the wells. DCFDA/ DAF-FM DA fluorescence signals were detected
2 and 6 hours after drug exposure using a VICTOR 3 plate reader (PerkinElmer, Waltham, MA).
Lipid Analysis by Mass Spectrometry
Equal number of cells (6 × 106 per well of a 6-well plate) were treated with indicated
drugs for 6 hours and lipids were extracted. Bioactive lipid levels were quantified at VCU
Lipidomics/Metabolomics Core Facility by liquid chromatography-electrospray ionizationtandem mass spectrometry (LC-ESI-MS/MS) with a Shimadzu LC-20AD binary pump HPLC
system (Shimadzu, Kyoto, Japan) and a 4000 QTRAP (Applied Biosystems, Carlsbad, CA)
operating in a triple quadruple mode as previously described by Hait et al., 2009.127
Immunoprecipitation
1X Chaps cell extract buffer was prepared according to the manufacturer’s protocol from
a 10X stock purchased from Cell Signaling Technology (#9852). 24 hours after treatment with
indicated drugs, cells were lysed in 1X Chaps buffer and scraped off into a 1.5 mL tube. Cells
were frozen at -80ºC and thawed at room temperature twice, and were spun down at 14,000 rpm
for 10 minutes. The supernatant was kept and pelleted cell debris was discarded. Concurrently,
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polystyrene beads (15 µm) (Nalgene, #114218900) were incubated with desired primary
antibody overnight. Beads were then washed with 1X PBS and were centrifuged at 5000 rpm for
2 minutes (this step was repeated at least two times). Cell lysates were then added to the
antibody-coated beads and were incubated overnight at 4ºC on a suitable shaker.
Immunoprecipitated complexes were collected by centrifugation at 5,000 rpm for 2 minutes, and
the supernatant was discarded. The pellet from the previous step was washed with 1X Chaps
buffer at least 3 times to remove any non-specific proteins or unbound antibody. Finally, SDS
sample buffer (as previously described in western blot analysis) was added to the pellets and
samples were heated at 100ºC for 5 minutes. Samples were then cooled on ice and were
subjected to western blot analysis.
Immunohistochemistry
In order to deparaffinize the sectioned tissues, Slides were heated in a Hybaid
hybridization oven (Thermo Scientific) at 60 ºC for 30 minutes and were then washed with
xylene substitute (Thermo Scientific, #9990505) three times (10 minutes each). Then, the slides
were washed for 5 minutes with 100% ethanol (Decon Labs, Inc., #2401), 95% ethanol and 70%
ethanol, respectively. In the next step, antigen retrieval was carried out using 10mM sodium
citrate (Sigma, #71497) buffer (pH 6.0). The samples were placed in the buffer, boiled for 15
minutes and were allowed to cool down in room temperature for 1.5-2 hours. Samples were
washed three times with 1X PBS and a hydrophobic line was drawn around each specimen using
an immunopen (Calbiochem, #402176). The samples were incubated for 1 hour with a blocking
buffer containing 1% BSA (Fisher Scientific, #138191) and 1% goat serum (Life Technologies,
#16210064) dissolved in TBST. After the blocking buffer was removed, the primary antibodies
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(1:200) followed by the fluorescent secondary antibodies (1:5000) were added and the slides
were viewed using the Hermes Wiscan instrument (IDEA Bio-Medical, Rehovot, Israel).
Tissue Microarray and Immunostaining
Human HCC tissue microarrays were purchased from Imgenex Corporation (San Diego,
CA). Two tissue microarrays were used: one containing 40 primary HCC, 10 metastatic HCC
and 9 normal adjacent liver samples (Imgenex, IMH-360), the other containing 46 primary HCC
and 13 metastatic HCC (Imgenex, IMH-318). Antigen retrieval was performed by the
Department of Pathology, VCU (with thanks to Dr. George Alemara). Immunostaining was
performed using anti-PDE5 antibody (1:50) or using a mixture of anti PDGFRα and antiPDGFRβ (1:50 for each) as described in the previous page under immunohistochemistry. After
immunostaining slides were stained in Harris hematoxylin solution for 8 minutes and were then
rinsed in running tap water. In the next step, differentiation was performed in 1% acid alcohol for
30 seconds and slides were washed again in running tap water. Bluing was done in 0.2%
ammonia water for 30 seconds to 1 minute and samples were rinsed again in tap water. Samples
were then counterstained with eosin-phloxine for 1 minute. Samples were then dehydrated
through 2 five-minute washes with 95% ethanol. Finally, slides were mounted with xylene-based
mounting medium and were examined by a confocal microscope.
Tissue Sectioning and H&E Staining
All harvested tissues and organs from animals were preserved in Formalin solution 10%
(Sigma, #SLBH1382V) for 24 hours and were sent out to the Biological Macromolecule Core
Facility at VCU for paraffin sectioning and H&E staining. Basic histology was performed at the
VCU Massey Cancer Center Macromolecule Core Facility, sponsored, in part, with funding from
NCI Cancer Core Grant P30 CA16059.
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Animal Studies
Athymic female NCr-nu/nu mice (National Cancer Institute) weighing 20-25 grams were
used for the human tumor xenograft studies. Mice were maintained in a pathogen-free vivarium
approved by the American Association for Accreditation of Laboratory Animal Care and in
accordance with current regulations and standards of the US Department of Agriculture, the US
Department of Health and Human Services, and the National Institute of Health. For each
experiment, ~40 mice (~10 per treatment group) were inoculated each with 5 × 106 cells in 100
µL (total) of Matrigel (BD, #354234) and 1X PBS (1:1 ratio), subcutaneously either into the
right rear flank (HUH7, HT29 and HT1080) or into the right fourth mammary fat pad (BT474).
Seven days after tumor implantation, mice were treated with either vehicle (1:1 ratio of
Cremophor EL (Sigma, #037K0213) and sterile water) or indicated drugs (dissolved in the same
solution as the vehicle) for 3-7 days (different for each experiment) by oral gavage. Animals
were monitored daily and the size (length and width) of each tumor was measured twice a week.
The tumor volumes were calculated using the formula (L×W2)/2. When the volume of the tumors
reached >1500 mm3, animals were humanely sacrificed and the tumor, blood and specific organs
were collected for further studies. Animal survival was plotted on a Kaplan-Meier graph and
longitudinal statistical assays were performed.
Multiplex Assay for Cytokine Expression
The Bio-Plex Multiplex Reader with associated software and all the related kits and
reagents were obtained from BIO-RAD (Hercules, CA). The collected blood plasma and tumors
from the animal experiments were assayed according to the manufacturer’s protocol and with
BIO-RAD technical assistance. The following Bio-Plex assay plates were used for the
assessment of human cytokines: Bio-Plex Pro Human Cytokine Group 14-Plex (Y500023JM2),
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Human CYTO STD GRPII 23-Plex (171D60001), Human CYTO HGF set (171B6008M),
Human CYTO SDF-1a set (171B6019M), Pro Human Cancer 2 18-Plex (171AC600M) and BP
Pro TGF-B 3-Plex (171W4001M).
Multiplex Assay for Signal Transduction Protein Phosphorylation and Expression
The following Bio-Plex assay plates were used to examine tumor cell signal transduction
proteins: Bio-Plex Pro Phosphoprotein magnetic 8-Plex (LQ000041XUYDC4), Bio-Plex Pro
Phosphoprotein magnetic 15-Plex (LQ000064Q3MJ1). Tumor lysates were assayed according to
the instructions provided by the manufacturer.
Data Analysis
The effects of various treatments were analyzed using one-way analysis of variance and a
two-tailed Student’s t-test. Median dose effect isobologram analysis to determine synergism of
drug interaction was carried out according to the methods of Chou and Talalay151 using the
CalcuSyn program for Windows (Biosoft). Based on this method, a combination index value of
< 1.00 indicates synergistic effect, a value of 1.00 indicates additivity, and a value of greater >
1.00 equates antagonism of action between the drugs. Statistical examination of in vivo animal
survival data utilized log rank statistical analyses between the different treatment groups. Results
with a P value of <0.05 were considered statistically significant. Experiments shown are the
means of multiple individual points from multiple experiments (±SEM).
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CHAPTER 3: Sildenafil Enhances the Toxic Effects of Sorafenib and Regorafenib in
Hepatoma and Colon Cancer Cells

Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer in the world, with
nearly half a million new cases per year.128-130 Major risk factors for this highly fatal cancer
include, hepatitis C, hepatitis B, heavy alcohol consumption, hemochromatosis, and
cirrhosis.128,129 Approximately 80% of the new HCC cases are diagnosed in Africa and Asia,
mainly due to the hepatitis B virus infection. However, the incidence of HCC has been rising
rapidly in the western world because of the high prevalence of hepatitis C virus infection.130
HCC is associated with poor prognosis, and the disease is generally diagnosed late in its
progression. Therefore, only ~30% of the patients are eligible for curative therapies, including
tumor resection and liver transplantation.128 Current curative and palliative treatments available
to the patients vary depending on the stage of the disease.128 They include:
1. Surgical resection: the optimal candidates for surgery are non-cirrhotic patients with
solitary non-metastatic lesions. The risk of recurrence 5 years after surgical resection is more
than 70%. There are no adjuvant or neoadjuvant therapies available to reduce the recurrence rate.
2. Orthotopic liver transplantation: transplantation just like surgery is among the best
treatments available for the patients diagnosed at early stage of their disease. However, due to a
shortage of organ donors, nearly 40% of the patients drop out because of tumor progression.128
3. Radiofrequency ablation (RFA): this method involves application of radiofrequency
thermal energy locally to the lesions, and induction of necrosis in the tissue surrounding the
electrode. This treatment is considered safe and effective for the patients ineligible for surgery.128
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4. Transarterial chemoembolization (TACE): since the majority of blood supply for the
hepatic tumors is received through the hepatic artery, injection of chemotherapeutic lipiodol
emulsion into the hepatic artery presents a feasible approach. The common chemotherapeutics
used in HCC treatment are adriamycin and cisplatin. However, this method has failed to provide
any survival advantage.128
5. Targeted therapy: due to the frequent deregulation of Raf/MEK/ERK pathway and
highly vascularized nature of HCC tumors, sorafenib became the first approved form of systemic
therapy in the treatment of HCC. However, sorafenib produced only a modest effect in a phase II
trial, where 33% of the patients showed stable disease for a period of 16 weeks.128 Therefore,
there is a substantial need to improve the clinical outcome of the systemic therapy in HCC.
Sorafenib
The bi-aryl urea sorafenib (BAY 43-9006, Nexavar) is an oral multi-kinase inhibitor,
which inhibits a wide range of targets, including Raf-1, B-Raf (wild type and mutant V600E),
VEGFR 1/2/3, PDGFRβ, FLT3, RET, and c-Kit with half maximal inhibitory concentration
(IC50) values in low nanomolar ranges.130-134 The development cycle of sorafenib (Figure 10)
took approximately 11 years and it was first approved by Food FDA in December 2005 for the
treatment of advanced renal cell carcinoma (RCC).132 Sorafenib was later approved as the first
systemic therapy in advanced HCC as monotherapy with this targeted agent was proven to
prolong overall survival and delay the progression time.131 Crystallographic studies of sorafenib
interaction with the kinase domain of B-Raf revealed that the drug bound to the ATP-binding
pocket, thus blocking substrate binding and phosphorylation.132 The steady-state plasma
concentrations for Sorafenib in patients who received 800 milligram daily dose of the drug (400
mg bid) were reached in 7 days, and its toxicity was well tolerated, with adverse effects limited
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to fatigue, diarrhea and hand or foot skin reactions.131 Sorafenib has an estimated half-life of 2548 hours, and is primarily metabolized in the liver via cytochrome P450 (CYP) 3A4.131 In vivo
and in vitro studies have indicated the ability of sorafenib to interrupt tumor growth and tumor
microvasculature through anti-proliferative, anti-angiogenic, and pro-apoptotic effects.134

Figure 10. Chemical structure of sorafenib.131

Colorectal Cancer
Colorectal cancer (CRC) is the fourth most prevalent cancer in men and the third most
common cancer in women worldwide.135 It is also the third most fatal cancer, claiming the lives
of almost a half a million people annually.136 Surgical resection followed by 5-FU-based
chemotherapy remains the standard of care for CRC patients.135-137 The current recommended
adjuvant treatments include: folinic acid + 5-FU + oxaliplatin (FOLFOX) or folinic acid + 5-FU
+ irinotecan (FOLFIRI) in combination with an anti-EGFR targeted agent such as bevacizumab,
cetuximab, or panitumumab. The use of anti-EGFR antibodies is not recommended in patients
with K-Ras mutations.135 Regorafenib is another targeted agent that initially got approved for the
treatment of metastatic CRC, but its approval was later expanded to include all the
gastrointestinal stromal tumors (GISTs).138 Lately, the sequential administration of regorafenib
with standard chemotherapy has been shown to have a promising effect with a manageable level
of toxicity.139 A phase II clinical study is currently investigating the potency of the combination
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of regorafenib and FOLFIRI in patients with K-Ras- or B-Raf-mutant CRC after a FOLFOX
regimen.139
Regorafenib
Regorafenib (BAY 73-4506, Stivarga) is an oral diphenylurea multi-kinase inhibitor that
is structurally similar to sorafenib. The addition of a fluorine atom in the central phenyl ring
makes it pharmacologically more potent than sorafenib (Figure 11).139 Just like sorafenib,
regorafenib have been shown to have an inhibitory effect on a broad range of kinases, including
Raf-1, B-raf (wild type and mutant V600E), VEGFR 1/2/3, PDGFRβ, FLT3, RET, c-Kit, p38,
tyrosine kinase with immunoglobulin and epidermal growth factor homology domain-2 (TIE-2),
an fibroblast growth factor receptor 1 (FGFR1).138-140 One of the major reasons of failure behind
antiangiogenic therapies is the infiltration of tumor-associated macrophages in the tumor
microenvironment. These TIE-2-expressing macrophages (TEMs) have been found in a variety
of tumors and are known to enhance angiogenesis and tumor progression. Therefore,
regorafenib, a TIE-2 and VEGFR inhibitor, is a more potent inhibitor of angiogenesis than
sorafenib.140 Regorafenib is metabolized primarily in the liver by CYP3A4, and its half-life has
been determined to be 20-30 hours.138 The recommended daily dose for regorafenib is 160 mg
with toxic side effects limited to skin rash, fatigue, hypertension, mucositis and diarrhea.138,139

Figure 11. Chemical structure of regorafenib.139
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Sildenafi Citrate
Manufactured by Pfizer, Sildenafil citrate (Viagra) was approved by FDA in March 1998
as the first orally active drug for the treatment of erectile dysfunction.141 Sildenafil is a potent
selective inhibitor of cGMP-specific PDE5, and has also been clinically approved for the
treatment of pulmonary hypertension.142 Sildenafil is rapidly absorbed and reaches maximum
plasma concentration (Cmax) within 1 hour after dosing. Sildenafil has a terminal half-life of ~4
hours, and is metabolized by hepatic enzymes CYP3A4 (major) and CYP2C9 (minor).142 The
adverse effects of sildenafil are limited to headache, flushing and dyspepsia.142

Figure 12. Chemical structure of sildenafil.141

Fingolimod
Developed by Novartis, fingolimod (FTY720, Gilenya) is a sphingosine 1-phosphate
(S1P) receptor agonist that was approved by FDA as the first oral agent for the treatment of
relapsing forms of multiple sclerosis (MS).143,144 Upon entering the blood circulation, fingolimod
is phosphorylated by sphingosine kinase 2 and converted to the S1P analogous form, Sfingolimod-phosphate. This active phosphorylated form of the drug is an agonist for the S1P
receptors.143,144 Further studies indicated that fingolimod acts as a functional antagonist leading
to S1P receptor internalization and degradation.143,144 Fingolimod causes retention of
lymphocytes in lymph nodes, thereby reducing the peripheral lymphocytes. It also crosses the
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blood brain barrier where it further reduces the severity of neuropathological outcomes of
MS.143,144 Fingolimod is very slowly absorbed and reaches Cmax in 12-24 hours. It has an
approximate half-life of 9-10 days, and is predominantly metabolized by CYP4F.144 The major
side effects of fingolimod are bradycardia and slowing of the atrioventricular conduction
accompanied by fatigue and dizziness.144

Figure 13. Chemical structure of fingolimod hydrochloride.143

The drug Combination Rationale
Prior studies from our laboratory demonstrated that PDE5 inhibitors enhanced the
toxicities of multiple chemotherapies.145,146 In these studies PDE5 inhibitors, in a NOSdependent fashion, were shown to enhance chemotherapy effect through activation of CD95
receptors, the generation of ROS, and mitochondrial dysfunction. Das et al147 have reported
similar results, further establishing a link between the activation of CD95 death receptor pathway
and sildenafil-mediated lethality. Additionally, other studies have indicated that sildenafil
reversed the ABCB1- and ABCG2-mediated MDR phenotype, leading to an increase in
intracellular concentration of chemothetrapeutics.148 Inhibition of major efflux pumps could also
be another contributing factor to the sildenafil-mediated enhanced chemotherapy. Furthermore,
several studies have reported increased PDE5 expression in multiple cancers, including
metastatic breast cancer, colon adenocarcinoma, bladder squamous carcinoma, and lung cancer,
implying a potential role in the cancer progression.147 Collectively, these discoveries suggested
that PDE5 inhibitors could be repurposed as targeted anti-cancer therapeutics. Therefore, we
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hypothesized that PDE5 inhibitors would enhance the effect of sorafenib, which is currently
approved for the treatment of HCC in the clinic. Since regorafenib is a more potent analogue of
sorafenib approved for the treatment of colon cancer, we later expanded our studies to evaluate
its interaction with sildenafil to kill colon cancer cells in vivo.
Later in our investigations, we also observed an increase in ceramides and S1P levels in
response to regorafenib. S1P has previously been linked to the induction of colitis-associated
cancer (CAC), and treatment with FTY720 has been shown to block CAC progression.149,150
Therefore, we hypothesized that the addition of FTY720 would enhance the lethality of
regorafenib individually or in combination with sildenafil in killing colon cancer cells.
Hypothesis
Inhibition of PDE5 enhances the toxicities of sorafenib and regorafenib through
activation of CD95 death receptor signaling, and NOS-dependent generation of ROS and RNS.

Table 1. Hepatic and colon cancer cell lines used in this study.
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Results
Sildenafil and sorafenib/regorafenib interact to kill hepatoma cells
Initial studies examined the dose-response of death receptor CD95 expressing HEP3B
cells to increasing concentrations of sorafenib (also referred to as SOR in the figures)
individually and in combination with sildenafil (also referred to as SIL in the figures). Sildenafil
enhanced sorafenib toxicity in HEP3B cells in a dose dependent fashion (Figure 14A). Sildenafil
(2 µM) also interacted with sorafenib (2 µM) to kill other hepatoma cells, regardless of whether
the cells expressed CD95, i.e., HUH7 cells are CD95 null (Figure 14B).
Regorafenib is a derivative of sorafenib with greater solubility and potency in vitro and in
vivo than the parent compound. The dose-response of death receptor CD95 null HUH7 cells to
increasing concentrations of regorafenib (also referred to as REGO/REG in the figures)
individually and in combination with sildenafil was examined. Similarly to sorafenib, sildenafil
enhanced regorafenib toxicity in a dose dependent fashion (Figure 15A). Sildenafil (2 µM) also
interacted with regorafenib (0.5 µM) to kill colon cancer cells (Figure 15B).
As previously stated, PDE5, the target of sildenafil, has been shown to be overexpressed
in multiple cancer types.147 In addition, in prior studies, we had demonstrated that PDGFRα/β
play an important role in the biology of sorafenib in terms of its toxic combination with other
therapeutics.152 Knockdown of PDE5 expression enhanced regorafenib toxicity in HUH7 cells
(Figure 16), and, similarly, knockdown of PDGFRα/β recapitulated the combinatorial effect of
sorafenib when combined with sildenafil. (Figure 17).
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Figure 14. Sorafenib and sildenafil interact to kill hepatoma cells. (A) HEP3B cells were
treated with vehicle (DMSO), increasing concentration of sorafenib (0.5-2 µM), and/or Sildenafil
(2 µM). Cells were isolated 24 hours after drug exposure and viability was determined via trypan
blue exclusion assay. (B) Hepatoma cells were treated with indicated drugs for 24 hours. Cells
were then isolated and subjected to trypan blue exclusion assay (n = 3, ± SEM). *P< 0.05 greater
than vehicle control.
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Figure 15. Regorafenib and sildenafil interact to kill hepatoma and colon cancer cells. (A)
HUH7 cells were treated with vehicle (DMSO), increasing concentration of regorafenib (3001500 nM), and/or Sildenafil (2 µM). Cells were isolated 24 hours after drug exposure and
viability was determined via trypan blue exclusion assay. (B) Colon cancer cells were treated
with indicated drugs for 24 hours. Cells were then isolated and subjected to trypan blue exclusion
assay (n = 3, ± SEM). *P<0.05 greater than vehicle control.
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Figure 16. Knockdown of PDE5 enhances regorafenib toxicity. HUH7 cells were transfected
with a control scrambled siRNA (siSCR) or three different siRNAs to knockdown expression of
PDE5. 36 hours after transfection, cells were treated with vehicle (DMSO), or regorafenib (0.5
µM), or sorafenib (2 µM). 24 hours after drug exposure, cells were isolated and viability
determined by trypan blue exclusion assay (n = 3, ± SEM). *P<0.05 greater than corresponding
value in siSCR cells.
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Figure 17. Knockdown of PDGFRα/β enhances sildenafil toxicity. HEP3B cells were
transfected with a control scrambled siRNA (siSCR) or two different siRNAs to knockdown
expression of PDGFRα and PDGFRβ. 36 hours after transfection, cells were treated with vehicle
(DMSO), or sildenafil (1-2 µM). 24 hours after drug exposure, cells were isolated and viability
determined by trypan blue exclusion assay (n = 3, ± SEM). *P<0.05 greater than corresponding
value in siSCR cells.
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The drug combination activates JNK1/2 and inhibits AKT, mTOR and ERK1/2
Treatment of HUH7 cells with the combination of regorafenib (0.5 µM) and sildenafil (2
µM) reduced the phosphorylation of p38, ERK1/2, AKT (T308) and mTOR (S2448), and
enhanced phosphorylation of JNK1/2 (Figure 18A). The drug combination also reduced the
phosphorylation of MEK1 (S218/S222). No obvious change was noted in MEK1 (S298)
phosphorylation (Figure 18B).
Next, we determined if the aforementioned alterations in the phosphorylation of key
signaling proteins affected the drug combination toxicity. Expression of activated forms of
MEK1 (caMEK1) or AKT (caAKT) partially suppressed the drug combination lethality whereas
activated form of mTOR (camTOR) or inhibition of JNK1/2 abolished the drug combination
toxicity in HEPG2 cells (Figure 19) and HUH7 cells (Figure 20).
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Figure 18. The REGO+SIL combination alters major signaling pathways. (A) HUH7 cells
were treated with vehicle (DMSO), regorafenib (0.5 µM), sildenafil (2 µM), or the drug
combination for 6 hours. Cells were lysed and expression of indicated proteins was determined
by western blot. (B) HUH7 and HT29 cells plated in 96-well plates were treated with indicated
drugs (REGO 0.5 μM + SIL 2µM). 6 hours after drug exposure, cells were fixed and probed with
the indicated antibodies. Images were acquired using a Hermes Wiscan system.
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Figure 19. Inhibition of JNK1/2 and activation of AKT, mTOR, and MEK1suppresses the
REGO+SIL combination lethality in HEPG2 cells. HEPG2 cells were transfected with
plasmids to express either empty vector (CMV), activated MEK1 (caMEK1), activated AKT
(caAKT), or activated mTOR (ca mTOR). 24 hours after transfection, cells were treated with
vehicle (DMSO) or regorafenib (0.5 µM) + sildenafil (2 µM) combination. Cell viability was
assessed 24 hours after drug exposure using a Hermes Wiscan instrument (n = 3, ± SEM). *P<
0.05 lower than corresponding value in CMV cells. For JNK1/2 inhibition, plated cells were
treated with the JNK inhibitory peptide (JNK-IP) for 30 minutes before the drugs were added
accordingly. The viability was determined in a similar way using a Hermes Wiscan instrument.
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Figure 20. Inhibition of JNK1/2 and activation of AKT, mTOR, and MEK1suppresses the
REGO+SIL combination lethality in HUH7 cells. HUH7 cells were transfected with plasmids
to express either empty vector (CMV), activated MEK1 (caMEK1), activated AKT (caAKT), or
activated mTOR (ca mTOR). 24 hours after transfection, cells were treated with vehicle (DMSO)
or regorafenib (0.5 µM) + sildenafil (2 µM) combination. Cell viability was assessed 24 hours
after drug exposure using a Hermes Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than
corresponding value in CMV cells. For JNK1/2 inhibition, plated cells were treated with the JNK
inhibitory peptide (JNK-IP) for 30 minutes before the drugs were added accordingly. The
viability was determined in a similar way using a Hermes Wiscan instrument.
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The drug combination induces ER stress
A major biological effect of sorafenib is the induction of ER stress/UPR, with reduced
expression of proteins that have short half-lives such as Mcl-1 and Bcl-xL.153,154 In this study,
treatment of HUH7 cells with the combination of regorafenib (0.5 µM) and sildenafil (2 µM)
increased the phosphorylation of PERK and eIF2α (Figure 21). Inhibition of PERK, ATF4 and
CHOP in HUH7 cells protected them from the drug combination toxicity (Figure 22).
The drug combination reduced the levels of Mcl-1 and GRP78. Worthy

Of note, the

drug combination also reduced the expression of ABCB1 and ABCG2 transporters (Figure 21).
To investigate these observations further in vivo, athymic mice were given vehicle diluent
(cremophor/ethanol), or sildenafil (5 mg/kg) and sorafenib (25 mg/kg) combination, or sildenafil
(5 mg/kg) and regorafenib (15 mg/kg) combination by oral gavage once a day. After 5 days of
treatment, mice were sacrificed, their brains and livers obtained and fixed. The tissues were
sectioned and subjected to immunohistochemistry and viewed at 10X magnification. In
accordance with the in vitro observations, the drug combination strongly down-regulated
GRP78, ABCB1 and ABCG2 in the liver and the brain tissues collected from the athymic mice.
The drug combination also weakly modulated other chaperones, including GRP94, HSP90 and
HSP70 (Figure 23).
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Figure 21. The REGO+SIL combination induces unfolded protein response. HUH7 cells
were treated with vehicle (DMSO), regorafenib (0.5 µM), sildenafil (2 µM), or the drug
combination for 6 hours. Cells were lysed and the expression of indicated proteins was
determined by western blot.
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Figure 22. Inhibition of the UPR components reduced the REGO+SIL combination
lethality. HUH7 cells were transfected with a control scrambled siRNA (siSCR) or two different
siRNAs to knockdown expression of ATF4 and CHOP, or cells were transfected with plasmids
to express either empty vector (CMV) or dominant negative PERK (dnPERK). 36 hours after
transfection, cells were treated with vehicle (DMSO), or regorafenib (0.5 µM) and sildenafil (2
µM) combination. 24 hours after drug exposure, cells were isolated and viability determined by
trypan blue exclusion assay (n = 3, ± SEM). *P< 0.05 lower than corresponding value in
siSCR/CMV cells.
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Figure 23. The REGO/SOR+SIL combination reduced expression of chaperones as well as
ABCB1 and ABCG2 transporters in vivo. athymic mice were given vehicle diluent
(cremophor/ethanol), or sildenafil (5 mg/kg) and sorafenib (25 mg/kg) combination, or sildenafil
(5 mg/kg) and regorafenib (15 mg/kg) combination by oral gavage once a day. After 5 days of
treatment, mice were sacrificed, their brains and livers obtained and fixed. The tissues were
sectioned and subjected to immunohistochemistry and viewed at 10X magnification.
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The drug combination induces the generation of ROS and RNS
Prior studies from our laboratory demonstrated that PDE5 inhibitors enhanced the
toxicities of multiple chemotherapies.145,146 In these studies PDE5 inhibitors, in a NOSdependent fashion, were shown to enhance chemotherapy effect through activation of CD95
receptors. PDE5 inhibitors are also known to enhance the levels of reactive oxygen and reactive
nitrogen species in treated cells.155,156 Treatment of tumor cells with sildenafil and sorafenib
combination rapidly increased the levels of ROS and RNS (Figure 24A). Inhibition of nitric
oxide synthase enzymes using L-NG-Nitroarginine Methyl Ester (L-NAME) reduced the drug
combination-mediated lethality, as did quenching of ROS production by incubating cells with Nacetyl cysteine (NAC) (Figure 24B). Knockdown of iNOS or eNOS expression suppressed
killing by the drug combination (Figure 25). Of note, knockdown of iNOS abolished the drug
combination interaction but did not alter sorafenib toxicity as a single agent, whereas knockdown
of eNOS significantly reduced sorafenib toxicity.
As the drug combination increased ROS and RNS levels, and L-NAME and NAC
protected the cells against the combination-mediated lethality, we determined whether ROS
regulated CD95 activation. Incubation of cells with NOS inhibitor, L-NAME, suppressed druginduced CD95 activation (Figure 26).
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Figure 24. SOR+SIL combination increases the generation of ROS and RNS. (A) HEPG2
cells were incubated for 30 minutes with either DCFDA, which is sensitive to oxidation by
hydroxyl radicals and peroxynitrite directly, and hydrogen peroxide, or DAF-FM DA, which is
sensitive to oxidation by NO. Cells were then treated with vehicle (DMSO), regorafenib (1 µM),
sildenafil (2 μM), or the drugs in combination. DCFDA/ DAF-FM DA fluorescence signals were
detected 2 and 6 hours after drug exposure using a VICTOR 3 plate reader. (B) HEPG2 cells
were pre-treated with vehicle, L-NAME (1 µM), or NAC (10 mM). Cells were then treated with
vehicle or sorafenib (2 µM) and sildenafil (2 µM) in combination. 24 hours after drug exposure,
cells were isolated and viability determined by trypan blue exclusion assay (n = 3, ± SEM). #P <
0.05 lower than corresponding value in VEH cells. ##P < 0.05 less than corresponding value in
NAC cells.
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Figure 25. Inhibition of iNOS and eNOS suppresses SOR+SIL combination toxicity.
HEPG2 cells were transfected with a control scrambled siRNA (siSCR) or two different siRNAs
to knockdown expression of iNOS and eNOS. 36 hours after transfection, cells were treated with
vehicle (DMSO), or sildenafil (2 µM) and sorafenib (2 µM) in combination. 24 hours after drug
exposure, cells were isolated and viability determined by trypan blue exclusion assay (n = 3, ±
SEM). #P<0.05 less than corresponding value in siSCR cells.
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Figure 26. Inhibition of NOS reduces the level of surface CD95 receptors. HEPG2 cells
plated in a 96-well plate were treated with vehicle or L-NAME (1 μM), then treated with vehicle
(DMSO), or sildenafil (2 µM) and sorafenib (2 µM) in combination. 6 hours after drug exposure,
cells were fixed and probed for CD95 expression. Images were acquired using a Hermes Wiscan
system.
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The drug combination induces autophagy
In prior studies, we have shown that sorafenib as a single agent can modestly promote
increased numbers of autophagosomes.50,152 As previously stated, lysosomal degradation of
autophagosomes results in a decrease in p62 levels, which makes p62 a suitable marker for
tracking autophagy in the mammalian cells.112 The level of p62 was reduced 6 hours after HUH7
cells were treated with the combination of regorafenib (0.5 µM) and sildenafil (2 μM) (Figure
27) Treatment of cells with the combination of sorafenib and sildenafil increased the numbers of
autophagosomes and autolysosomes in a greater than additive fashion (Figure 28A). The increase
in the numbers of autophagosomes was suppressed when cells were pre-treated with L-NAME
and NAC, establishing a link between the ROS generation and the induction of autophagy
(Figure 28B). The knockdown of autophagy components ATG5 and Beclin1 reduced the drug
combination lethality in HEP3B and HUH7 cells (Figure 29).
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Figure 27. The REGO+SIL combination reduces p62 level. HUH7 cells were treated with
vehicle (DMSO), regorafenib (0.5 µM), sildenafil (2 µM), or the drug combination for 6 hours.
Cells were lysed and the expression of p62 was determined by western blot.
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Figure 28. The SOR+SIL combination induces formation of autophagosomes and
autolysosomes. (A) HEPG2 cells were transfected with a plasmid to express LC3-GFP-RFP. 24
hours after transfection, cells were treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2
µM), or the combination of both drugs. The number of GFP vesicles (early autophagosomes) and
RFP vesicles (late autolysosomes) were determined 6 and 24 hours after drug exposure. (B)
LC3-GFP-RFP transfected cells were pre-treated with L-NAME (1 µM) and NAC (10 mM), and
then exposed to the combination of sorafenib (2 µM) and sildenafil (2 µM). The number of GFP
and RFP vesicles were determined 6 and 24 hours after drug treatment (n = 3, ± SEM). *P< 0.05
lower than corresponding value in control group.
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Figure 29. Inhibition of autophagy reduced the SOR+SIL combination toxicity. HUH7 and
HEP3B cells were transfected with a control scrambled siRNA (siSCR) or two different siRNAs
to knockdown expression of ATG5 and Beclin1. 36 hours after transfection, cells were treated
with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the combination of both drugs. 24
hours after drug exposure, cells were isolated and viability determined by trypan blue exclusion
assay (n = 3, ± SEM). *P< 0.05 lower than corresponding value in siSCR cells.
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The drug combination activates extrinsic and intrinsic apoptosis pathways
In our previous studies, we have described how sorafenib can interact with agents that
generate ROS to facilitate activation of the death receptor CD95.152 In these studies HUH7 cells,
which lack endogenous CD95 expression, were particularly resistant to the tested sorafenib drug
combinations. However, in this study, we have found that sorafenib and sildenafil interact to kill
both CD95 null HUH7 cells and hepatoma cells that express CD95 (HEP3B and HEPG2),
though the drug combination killing appears to be more efficient in HEP3B and HEPG2 cells
(Figure 14B). Thus, we next determined whether inhibition of the extrinsic and/or intrinsic
apoptosis pathways could suppress drug combination-mediated toxicity. Expression of Bcl-xL
and dominant negative caspase 9 that suppress activation of the intrinsic apoptosis pathway
protected both HEPG2 and HUH 7 cells (Figure 30). Expression of the caspase 8 inhibitor cFLIP-s protected HEPG2 cells, suggesting that the activation of extrinsic apoptosis pathway
played a role in cell killing. Expression of c-FLIP-s did not alter the cell death response in HUH7
cells (Figure 30). We further explored signaling by the extrinsic pathway in by looking at
caspase 8 and FADD levels associated with CD95. Both caspase 8 and FADD rapidly increased
in response to the drug combination (Figure 31A). In addition, Inhibition of FADD and CD95
reduced the cell death in HEP3B cells (Figure 31B). Finally, expression of wild type CD95 in
HUH7 cells enhanced cell killing by sorafenib and the combination of sorafenib and sildenafil
whereas expression of a mutant CD95, lacking the specific tyrosine residues required for
activation, did not alter cell death (Figure 32).
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Figure 30. The SOR+SIL combination activates extrinsic and intrinsic apoptosis pathways.
HUH7 and HEPG2 cells were infected with recombinant adenoviruses to express empty vector
(CMV), dominant negative caspase 9 (dn casp 9), Bcl-xL, or c-FLIP-s. 24 hours after infection
cells were treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the combination
of both drugs. 24 hours after drug exposure, cells were isolated and viability determined by
trypan blue exclusion assay (n = 3, ± SEM). #P< 0.05 lower than corresponding value in CMV
cells.
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Figure 31. The SOR+SIL combination activates CD95 death receptors. (A) HEPG2 cells
were treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the combination of
both drugs. 6 hours after treatment, cells were lysed and prepared for immuoprecipitation (IP) of
CD95. After IP, immunoblotting was performed to determine the levels of caspase 8 and FADD
in the immunoprecipitate. Total levels of CD95 and GAPDH in the lysates are also presented.
(B) HEP3B cells were transfected with a control scrambled siRNA (siSCR) or two different
siRNAs to knockdown expression of FADD and CD95. 36 hours after transfection, cells were
treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the combination of both
drugs. 24 hours after drug exposure, cells were isolated and viability determined by trypan blue
exclusion assay (n = 3, ± SEM). #P< 0.05 lower than corresponding value in siSCR cells.
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Figure 32. CD95 expression enhances SOR+SIL combination toxicity in HUH 7 cells.
HUH7 cells were transfected with plasmids to express either empty vector (CMV), a plasmid to
express CD95-GFP, or a plasmid to express CD95-GFP-Y232F Y291F. 24 hours after
transfection, cells were treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the
combination of both drugs. 12 hours after drug treatment, cell viability was assessed using a
Hermes Wiscan instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in CMV
cells.
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The drug combination increases the ceramide levels
Prior reports from our group have shown that sorafenib can increase the levels of
ceramides in hepatoma cells.152 In accordance with our previous findings, regorafenib and
sildenafil treatment increased the levels of multiple ceramide and dihydro-ceramides in HUH7
cells (Figure 33). Regorafenib also increased the levels of sphingosine-1 phosphate (Figure 34).
The approved multiple sclerosis drug FTY720 (fingolimod, Gilenya) inhibits the production of
S1P as an active site inhibitor of sphingosine kinase 1 and 2.143,144 Treatment of cells with low
clinically relevant concentration s of FTY720 suppressed the ability of regorafenib to increase
S1P (Figure 34).
We next determined if FTY720 can enhance the toxicity of the combination of
regorafenib and sildenafil. Our data indicated that the addition of FTY720 to the drug
combination significantly increased percentage cell death in HUH7 and HT29 cells (Figure 35).
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Figure 33. The REGO+SIL combination increases ceramide levels. HUH7 cells were treated
with vehicle (DMSO), regorafenib (0.5 µM), sildenafil (2 µM), or the drug combination for 6
hours. Cells were then isolated and bioactive lipids were extracted. Multiple bioactive lipids
were analyzed using GC/MS techniques (n=2 in triplicate ±SEM). *P< 0.05 greater than
corresponding value in VEH cells.
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Figure 34. Regorafenib increases S1P levels. HUH7 cells were treated with vehicle (DMSO) or
regorafenib (0.5 µM), and/or Fumonisin B1 (25 μM) or FTY720 (50 nM). 6 hours after
treatment, cells were isolated and bioactive lipids were extracted. S1P levels were analyzed using
GC/MS techniques (n=2 in triplicate ±SEM). *P< 0.05 greater than corresponding value in VEH
cells. #P< 0.05 lower than corresponding value in regorafenib-treated VEH cells.
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Figure 35. FTY720 enhances REGO+SIL combination-mediated toxicity. HUH7 and HT29
cells were treated with vehicle (DMSO), regorafenib (0.5 µM) and sildenafil (2 µM)
combination, FTY720 (50 nM), or the combination of all three drugs. 12 hours after drug
treatment, cell viability was assessed using a Hermes Wiscan instrument (n = 3, ± SEM). *P<
0.05 greater than corresponding value in SIL+REGO cells.
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Sildenafil interacts with sorafenib/regorafenib to kill tumor cells in vivo
We next determined whether sorafenib/regorafenib interacted with sildenafil in vivo to
kill tumor cells. Initial studies examined the ex vivo plating efficiency of tumor cells treated in
vivo with regorafenib and sildenafil. Treatment of cells with sildenafil (5 mg/kg) and regorafenib
(25 mg/kg) in vivo caused a reduction in ex vivo plating efficiency of isolated tumor cells
following drug exposure; thus the long-term colony forming ability of the drug-treated cells was
reduced beyond that achieved due to the proximal anti-tumor effects of the individual drugs
(Figure 36A). We then performed additional studies using preformed HUH7 tumors (~150 mm3).
In our prior studies, HUH7 cells had a significantly greater tumorigenic potential than either
HEPG2 or HEP3B cells to grow in an athymic mouse. Due to the lack of CD95 expression in
these cells, the relative effect of the drug combination might be less efficient even though data
from previous figure (Figure 36A) argues than interaction between the two drugs occurs in vivo.
Transient treatment of animals with sildenafil (5 mg/kg) did not alter tumor growth whereas
treatment with sorafenib (25 mg/kg) caused a non-significant trend towards reduced growth.
Combined treatment of mice with both drugs for 3 days caused a significant reduction in HUH7
tumor growth (Figure 36B).
Based on the data from FTY720 interaction with the drug combination (Figure 37), we
then determined if FTY720 interacted with regorafenib and the combination of regorafenib and
sildenafil to kill HT29 cells in vivo (Figure 37). FTY720 (0.05 mg/kg) as a single agent, had a
modest effect on reducing tumor growth but did cause a modest significant increase in overall
survival (Figure 37 and 38). Surprisingly, we found that a transient 7-day treatment of HT29
tumors with regorafenib and FTY720 or with regorafenib (25 mg/kg) and sildenafil (5 mg/kg)
and FTY720 caused tumors exposed to FTY720 to re-grow at a much faster rate after cessation
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of drug treatment than either regorafenib treatment alone or treatment with regorafenib and
sildenafil (Figure 37). The growth of tumors treated with the combination of regorafenib and
sildenafil was profoundly reduced both during and for many weeks following the cessation of
treatment, which was reflected in a significant increase in animal survival (Figure 38).
Morphological examination of the tumors in situ in the mouse flank (pictures were
chosen with tumors in each condition at the same approximate volume) demonstrated that the
tumors treated with FTY720 exhibited a more vascularized appearance on their surface (Figure
39). H&E staining of sectioned tissues of multiple organs collected from the vehicle group and
the group that received the combination of regorafenib and sildenafil indicated that the drug
combination did not damage the normal tissues (Figure 40).
In addition to previous in vivo studies, we also collected portions of the tumors from each
group at the time of sacrifice. The tumors were digested and single cells were plated to determine
the ex vivo plating efficiency of cells. Treatment of tumors with FTY720 individually, that had a
marginal effect on tumor growth and animal survival, significantly reduced ex vivo plating
efficiency (Figure 41). Regorafenib as a single agent did not alter ex vivo colony formation that
correlated with our tumor growth and survival findings and with the clinical data where
regorafenib has only a ~1% response rate. The reduced plating efficiency of tumors treated with
regorafenib and sildenafil correlated with suppressed tumor growth and increased animal
survival.
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A

B

Figure 36. The drug combination suppresses tumor growth in vivo. (A) HUH7 and HCT116
tumors were formed in the flank of athymic mice (~150 mm3). Animals were treated with vehicle
(cremophor/ethanol), sildenafil (5 mg/kg), regorafenib (25 mg/kg), or the combination. Tumors
were isolated, digested and single cells were plated. Colonies were permitted to form in 7-10
days. Colonies were then fixed, stained and counted. Survival value in the vehicle group was
defined as 100% (n=6 ±SEM). #P< 0.05 lower than corresponding value in regorafenib-treated
cells. (B) HUH7 tumors were formed in the flank of athymic mice (~150 mm3). Animals were
treated with vehicle (cremophor/ethanol), sildenafil (5 mg/kg), sorafenib (25 mg/kg), or the
combination for 3 days. Tumor volumes were measure 7 and 14 days after the start of the
treatment. (n=2 studies, 8 animals per group ± SEM). #P< 0.05 less than sorafenib-treated cells.
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Figure 37. Regorafenib interacts with sildenafil to kill HT29 cells in vivo. HT29 tumors were
formed in the flank of athymic mice (~30 mm3). Animals were treated with vehicle
(cremophor/ethanol), sildenafil (5 mg/kg) and regorafenib (25 mg/kg), FTY720 (0.05 mg/kg) or
the combination of all drugs for 7 days. Tumor volumes were measured every 4 days after the
end of the drug treatment (n = 2 studies, 8 animals per group ± SEM).
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Figure 38. Combination of regorafenib and sildenafil significantly increased the survival
time. Kaplan Meier survival plot of animals treated in previous study (Figure 39); animals were
humanely sacrificed when tumor volumes exceeded 1500 mm3.
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Figure 39. HT29 tumors pictured between days 15-30. Representative images of tumors from
each group were taken between days 15 and 30 when tumors were of approximately the same
volume. Tumors from the FTY720-treated groups have a more vascularized appearance.
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Figure 40. The REGO+SIL combination did not damage the normal tissue. Vital organs
were collected from the mice that received the vehicle (cremophor/ethanol) or the combination
of regorafenib and sildenafil for 7 days. Tissues were sectioned and H&E stained, and were
examined under 10X magnification.
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Figure 41. The REGO+SIL combination significantly reduced the ex vivo plating efficiency.
HT29 tumor cells, at the time of sacrifice, were isolated and gently digested to obtain a single
cell suspension of tumor cells. Cells were plated as single cells 100-10,000 per well of a 6-well
plate. Colonies were permitted to form in 7-10 days. Colonies were then fixed, stained and
counted, and plating efficiency was determined (n=8 ± SEM). #P< 0.05 lower than
corresponding value in VEH and REGO-treated cells.
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The drug combination alters the cytokine expression levels in mouse plasma
Based on our in vivo findings, we determined the expression levels of human cytokines in
mouse plasma and activity of signal transduction proteins within the established tumor itself.
Regorafenib and sildenafil exposure for 7 days decreased the plasma levels of bFGF and GMCSF but significantly increased PDGFbb (Figure 42A). Treatment of tumors with FTY720 for 7
days increased plasma levels of FAS-L (Figure 42B). For a number of cytokines, including
endoglin, IL-6, VEGF-A/C/D, endopoietin 2, and EGF the plasma level declined in vehicle
control treated tumors over 7 days of growth, which was associated with a mean of
approximately seven fold increase in tumor volume (Figure 42B-F). In this respect, treatment of
tumors with FTY720 or with regorafenib and FTY720 combination prevented the decline in
plasma cytokine levels that were observed in mice with vehicle control treated tumors at day 7
(Figure 42B-G). For tumors exposed to regorafenib and sildenafil, the expression of pro-growth,
pro-angiogenic, and pro-invasion cytokines was either unchanged compared to the vehicle
control or was significantly reduced (Figure 42C-G).
Additionally, treatment of tumors with regorafenib and FTY720 combination increased
the expression of pro-growth/pro-angiogenic/pro-invasion cytokine endoglin, which enhances
TGFβ signaling (Figure 42G). as treatment of tumors with FTY720 caused an increase in
endoglin expression, which would enhance TGFβ receptor family as well as integrin signaling,
we determined whether the toxicity of regorafenib and FTY720 combination was enhanced in
vitro using TGFβ inhibitor LY2157299 (Galunisertib). Our data indicated that the inhibition of
TGFβ receptor 1 signaling in a dose-dependent fashion significantly enhanced the toxicity of
regorafenib+FTY720 combination (Figure 43).
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A

Figure 42. The drug combination alters the cytokine expression levels in mouse plasma. (AG) HT29 tumors (~30 mm3) were formed in the flanks of athymic mice. Aliquots (~75 μL) of
mouse blood were obtained in a heparin/EDTA coated Eppendorf tube. Animals were then
treated with vehicle diluent (cremophor/ethanol), sildenafil (5 mg/kg) and regorafenib (25
mg/kg), FTY720 (0.05 mg/kg) or the combination of all drugs for 7 days. Data in part A are
vehicle control and the combination of regorafenib and sildenafil tumor data. After 7 days
aliquots of mouse blood were obtained again. Clarified mouse plasma free of blood cells was
then subjected to multiplex assays in a BIO-RAD MAGPIX system to determine the expression
of the indicated cytokines before and following treatment (n=2 studies, 8 animals per group ±
SEM). *P< 0.05 greater than day 0 pre-treatment value. **P< 0.05 greater than day 7 vehicle
control value. #P< 0.05 less than day 0 pre-treatment value. ##P< 0.05 less than day 7 vehicle
control value. лP< 0.05 less than day 7 regorafenib treatment value.
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Figure 43. Inhibition of TGFβ signaling enhances the toxicity of regorafenib and FTY720
combination. HT29 and HCT116 cells were treated with vehicle (DMSO), regorafenib (0.5 μM)
and FTY720 (50 nM) combination, LY2157299 (2, 6 μM), or the combination of all drugs as
indicated. 12 hours after drug treatment, cell viability was assessed using a Hermes Wiscan
instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in REGO+FTY cells.
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The drug combination alters multiple signaling pathways
We also collected tumor and blood materials at the time of humane sacrifice of the mice
from our HT29 experiment. Most notably the expression of growth factors bFGF and PDGFbb
were elevated and the expression of GM-CSF reduced (Figure 44A). This was associated with
increased AKT activity and reduced p70S6K phosphorylation (Figure 44B). Changes in receptor
phosphorylation or transcription factor phosphorylation were not significant (Figure 44C and D).
Based on our data showing that drug-treated tumors had stable high EGFR phosphorylation,
expressed more FGF and had higher AKT activity, we determined the impact of the inhibitors of
EGFR (lapatinib), FGFR (BGJ398), and AKT (MK2206) on the toxicity of regorafenib and
sildenafil combination. Inhibition of either AKT or EGFR enhanced the lethality of regorafenib
and sildenafil combination (Figure 45).
We then determined the activities of multiple signal transduction pathways/proteins in
tumors collected 7 days after the start of the treatment. Treatment of HUH7 and HT29 tumors
with the combination of regorafenib and sildenafil reduced plasma levels of FGF and GM-CSF
and increased the levels of PDGFbb (Figure 42A and 46A). Regorafenib and sildenafil treatment
also reduced the expression of multiple tumor growth factors in the blood of mice carrying
HUH7 tumors (Figure 46B). In both HUH7 and HT29 tumors, the drug combination caused
activation of AKT though total p70S6K phosphorylation was reduced in both tumor types
(Figure 48C). These findings were associated with reduced PDGFRβ phosphorylation and
decreased NFκB activity (Figure 46D and E). Based on the biomarkers for activated
compensatory survival pathways, the candidates for third drug combinations include AKT
inhibitors, FGFR inhibitors, and EGFR inhibitors. The impact of such inhibitors on the toxicity
of regorafenib and sildenafil were validated in vitro (Figure 45).
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Figure 44. The drug combination alters multiple signaling pathways in tumor cells. (A-D)
HT29 tumors isolated from the vehicle control or the combination of regorafenib and sildenafiltreated mice collected at the time of sacrifice were subjected to multiplex assays in a BIO-RAD
MAGPIX instrument to determine the expression of cytokines in plasma and the phosphorylation
of the indicated signal transduction proteins (n=8 ± SEM). ~P< 0.05 greater than vehicle control
value. #P< 0.05 less than corresponding vehicle control value.
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Figure 45. AKT, FGFR and EGFR inhibitors enhance the REGO+SIL combination
lethality. HT29 cells were treated with vehicle (DMSO), regorafenib (0.5 μM) and sildenafil (2
μM) combination, lapatinib (1 μM), MK2206 (1 μM), BGJ398 (1 μM), or the combinations as
indicated in the figure. 12 hours after drug treatment, cell viability was assessed using a Hermes
Wiscan instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in REGO+SIL
group.
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Figure 46. Multiplex analysis of tumors collected at the time of sacrifice. (A-E) HT29 and
HUH7 tumors isolated from the vehicle control or the combination of regorafenib and sildenafiltreated mice collected at the time of sacrifice were subjected to multiplex assays in a BIO-RAD
MAGPIX instrument to determine the expression of cytokines in plasma and the phosphorylation
of the indicated signal transduction proteins (n=8 ± SEM). ~P< 0.05 greater than vehicle control
value. #P< 0.05 less than corresponding vehicle control value.
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Discussion
Our data demonstrated that PDE5 inhibitor sildenafil and sorafenib/regorafenib interact to
kill a genetically diverse set of hepatic and colon cancer cells in vitro and in vivo. Prior studies
from our laboratory demonstrated that PDE5 inhibitors enhanced the toxicities of multiple
chemotherapies.145,146 In these studies PDE5 inhibitors, in a NOS-dependent fashion, were shown
to enhance chemotherapy effect through activation of CD95 receptors, the generation of ROS,
and mitochondrial dysfunction. In addition, in prior studies, we had demonstrated that
PDGFRα/β play an important role in the biology of sorafenib and regorafenib in terms of its
toxic combination with other therapeutics.152 In agreement with our previous studies, knockdown
of PDE5 recapitulated the combinatorial effect of a PDE5 inhibitor when combined with
sorafenib whereas knockdown of PDGFRα/β recapitulated the combinatorial effect of sorafenib
when combined with sildenafil. Thus, we further validated that the inhibition of PDE5 and
PDGFRα/β does indeed play a major role in the induction of cell death by the drug combination.
PDE5 inhibitors are known to enhance cGMP and NO levels; inhibition of NOS enzymes by LNAME reduced the drug combination-mediated toxicity.
In our previous studies, we had described how sorafenib can interact with agents that
generate ROS to facilitate activation of the death receptor CD95.152 In these studies HUH7 cells,
which lack endogenous CD95 expression, were particularly resistant to the tested sorafenib drug
combinations. However, in this study, we have found that sorafenib and sildenafil interact to kill
both CD95 null HUH7 cells and hepatoma cells that express CD95 (HEP3B and HEPG2),
though the drug combination killing appears to be more efficient in HEP3B and HEPG2 cells. In
order to further validate the role of death receptor CD95 signaling in drug combination-mediated
cell death, we transfected HUH7 cells with a plasmid expressing wild type CD95, and managed
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to immensely increase the combination-mediated lethality in these cells. Moreover, in cells
expressing CD95, inhibition of both extrinsic and intrinsic apoptosis pathways suppressed the
drug combination toxicity whereas in HUH7 cells cell death was due to the activation of intrinsic
pathway. We also showed that activation of CD95 receptors was suppressed by inhibition of
NOS enzymes. Studies by others have shown that nitrosylation of CD95 at its regulatory tyrosine
residues inhibit CD95 signaling.157 However, others have argued that NO signaling and
activation of CD95 can cooperate to induce cell death.158
The drug combination also increased the numbers of autophagosomes and autolysosomes
in a time dependent fashion that was inhibited by incubation of the cells with L-NAME and
NAC. Inhibition of autophagy reduced cell death caused by the drug combination. NO signaling
has been linked by others to the regulation of autophagy as in some primary non-transformed
cells NO can inhibit autophagy by inhibiting JNK signaling.159,160 However, in some transformed
cells NO signaling can promote autophagy in an mTOR-dependent fashion, which seems to play
a role in tumor cell death.161,162 In this study, we demonstrated that the drug combination
inactivated mTOR, and expression of an activated mTOR suppressed killing. Activation of the
JNK pathway played a key role in the drug combination-mediated lethality. Therefore, NO
signaling plays a role in de-repressing a brake on toxic autophagy (mediated by mTOR) as well
as promoting activation of CD95-mediated apoptosis.
The drug combination rapidly increased the levels of ROS and RNS. Inhibition of NOS
enzymes almost abolished cell killing caused by the drug combination whereas quenching of
ROS by NAC was partially protective. In accordance with these findings, knockdown of iNOS
and eNOS was also protective. One important mechanism by which NO is inactivated is by
reaction with the superoxide anion (O2-).163 Compared to non-transformed cells, tumor cells
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generate considerably greater amounts of O2-.164 As mentioned before, NOS activity depends on
several cofactors, including NADPH and BH4. BH4 plays a critical role in NOS activity. Small
ratio of BH4 relative to its oxidized form, BH2, causes NOS uncoupling, leading to production
of ROS and RNS rather than NO, a phenomenon commonly observed in cancer cells.87,89 Thus,
whereas sildenafil is often associated with reduced oxidative stress in non-transformed cells, it
promotes oxidative stress in tumor cells.156 The reaction of NO with O2- forms the most potent
oxidant peroxynitrite (ONOO-).165 Peroxynitrite causes oxidative damage and S-nitrosylation of
proteins, lipids, and DNA.166 Nitrosative stress by ONOO- has been implicated in DNA
breakage, followed by PARP and ATM/ATR activation.167 Further studies will be required to
determine whether ATM/ATR signaling plays any role in the regulation of apoptosis/autophagy
pathways and signal transduction pathways.
As previously stated, a major biological effect of sorafenib is the induction of ER
stress/UPR, with reduced expression of proteins that have short half-lives such as Mcl-1 and BclxL.153,154 In agreement with these reports, the drug combination in this study also induced UPR
as the levels of phospho-PERK and phospho-eIF2α rapidly increased within 6 hours after drug
exposure. Of note, in addition to a reduction in Mcl-1 and GRP78 levels, the levels of multiple
other chaperones such as GRP94, HSP90 and HSP70 as well as the ABC transporters ABCB1
and ABCG2 were significantly reduced in vivo as shown by immunohistochemistry data. Further
investigations from our laboratory indicated that the combination of sildenafil and
regorafenib/sorafenib reduced the levels of a wide range of surface receptors, including the
receptors involved in viral and bacterial infections, which further highlighted the therapeutic
value of chaperones, most notably GRP78, in treatment of multiple human diseases.126,168
Inhibition of the UPR components such as PERK, ATF4 and CHOP significantly reduced the
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drug combination lethality. Prior studies by our colleagues had reported that sorafenib treatment
induced ER stress and activation of caspase 2 and 4, which directly induce apoptosis.153 The role
of ER-specific caspase activation was not explored in this study. However, our data argues that
the ER stress is involved in the drug combination-induced cell death.
Based on our encouraging in vitro data, we moved our studies forward using several
animal model systems in athymic mice. Short-term exposure to sildenafil and regorafenib killed
tumor cells as judged by ex vivo colony formation assays. Long-term exposure to sildenafil and
sorafenib suppressed HUH7 tumor growth over several weeks. This is of note as HUH7 cells,
which lack CD95, would be predicted based on in vitro data to respond relatively poorly to the
drug combination. Similarly, the growth of HT29 tumors treated with the combination of
regorafenib and sildenafil was profoundly reduced both during and for many weeks following
the cessation of treatment, which was reflected in a significant increase in animal survival. The
drug combination anti-tumor activity in vivo is likely an amalgamation of a direct anti-tumor cell
killing effect by the drug combination and increased tumor vasculature permeability caused by
the actions of sildenafil on endothelial cells.169 During our in vitro studies, we also noted an
increase in ceramides and S1P in response to regorafenib treatment. S1P has previously been
linked to the induction of colitis-associated cancer (CAC), and treatment with FTY720 has been
shown to block CAC progression.149,150 Our in vitro studies indicated that the addition of
FTY720 to the drug combination significantly enhanced cell death in HT29 and HUH7 cells.
Therefore, we determined whether FTY720 could replicate the same effect in the mouse models.
To our surprise, FTY720-treated tumors resulted in an unexpected stronger re-growth of tumors
after cessation of drug treatment than the tumors treated with regorafenib or the regorafenib and
sildenafil combination. Images taken from the tumors indicated that the FTY720-treated tumors
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had a more vascularized appearance. Multiplex analysis of cytokines in the blood of animals
treated with FTY720 collected at day 7 revealed a significant increase in angiogenic factors,
including VEGF-A, VEGF-D and angiopoietin. Additionally, treatment of tumors with
regorafenib

and

FTY720 combination increased the

expression of pro-growth/pro-

angiogenic/pro-invasion cytokine endoglin, which enhances TGFβ signaling. Thus, we
determined whether the toxicity of regorafenib and FTY720 combination was enhanced in vitro
using TGFβ inhibitor LY2157299 (Galunisertib). Our data indicated that the inhibition of TGFβ
receptor 1 signaling in a dose-dependent fashion significantly enhanced the toxicity of
regorafenib and FTY720 combination.
Based on our multiplex analysis data from the collected tumors and blood from the
animals at the time of sacrifice, we found that drug combination-treated tumors had stable high
EGFR phosphorylation, expressed more FGF and had higher AKT activity. Consequently, we
determined the impact of the inhibitors of EGFR (lapatinib), FGFR (BGJ398), and AKT
(MK2206) on the toxicity of regorafenib and sildenafil combination. Inhibition of either AKT or
EGFR enhanced the lethality of regorafenib and sildenafil combination. Thus, the activation of
AKT and EGFR in response to the regorafenib and sildenafil combination seems to be the major
compensatory survival pathways.
As the drugs used in this study are all FDA approved agents, our data argue for further
determination as to whether sorafenib/regorafenib and sildenafil can interact in the same fashion
in the clinic. Recently, a clinical trial in Massey Cancer Center (NCT02466802) evaluating the
combination of regorafenib and sildenafil in all solid tumors has opened.
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Figure 47. Proposed mechanism of the SOR/REGO+SIL combination-mediated cell death.
The drug combination inhibited PDE5, thus increasing the levels of ROS and RNS in a NOSdependent fashion. The generation of ROS was shown to activate death receptor CD95 signaling.
The drug combination also inhibited ERK1/2 and AKT, and activated JNK1/2. Inhibition of
AKT/mTOR pathway activated a toxic form of autophagy. In addition, the drug combination
induced the UPR; resulting in an increase in transcription of CHOP. The induction of ER stress
by the drug combination was shown to be involved in mediating cell death.(Guide:
represents
explored pathways,
represents unexplored but feasible pathways)
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Conclusion
Collectively, our data from this study demonstrated that sorafenib/regorafenib interacts
with sildenafil to kill a genetically diverse set of hepatic and colon cancer cells in vitro and in
vivo in a process that involves ER stress, autophagy, and intrinsic and extrinsic apoptotic
pathways. The drug combination rapidly increased the levels of ROS and RNS in a NOSdependent fashion. Incubation of cells with L-NAME, a NOS inhibitor, suppressed drug
combination-induced CD95 activation. Long-term exposure to sildenafil and sorafenib
suppressed HUH7 tumor growth over several weeks. Similarly, the growth of HT29 tumors
treated with the combination of regorafenib and sildenafil was profoundly reduced both during
and for many weeks following the cessation of treatment, which was reflected in a significant
increase in animal survival. By applying multiplex technology, we were able to predict and
validate various signaling biomarkers with AKT and EGFR being identified as major
compensatory survival responses to the drug combination.
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CHAPTER 4: Ruxolitinib and EGFR Inhibitors Interact to Kill Breast Cancer Cells in a
Synergistic Fashion
Breast Cancer
Breast cancer is the leading cause of death in women worldwide. According to World
Health organization (WHO), in 2012 breast cancer accounted for 23% of all cancer deaths across
the globe.170 The same year in the US, 200,000 new cases were diagnosed with about 40,000 of
the patients losing their lives, making it the second deadliest disease among women after lung
cancer.171 Early detection due to screening, more effective adjuvant therapies, and lower rates of
hormone replacement therapies have contributed to the declining mortality rates in the recent
years.171 Breast cancer is generally classified into three categories: hormone receptor (ER)
positive, HER2 positive and triple negative breast cancer (TNBC).171 Current treatments for
breast cancer include: Surgery (breast-conserving or total mastectomy), radiation therapy,
chemotherapy, hormone therapy, and targeted therapy.
Hormone receptor positive carcinomas account for nearly 70% of all breast cancers.172
Adjuvant hormonal therapy with tamoxifen has been the standard therapy for postmenopausal
women with ER positive breast cancer.173 Recently, nonsteroidal aromatase inhibitors, such as
letrozole and anastrozole have been shown to have superior effects over tamoxifen in reducing
circulating estrogen levels. These compounds are currently approved by FDA for the fist- and
second-line treatment of ER positive metastatic breast cancer.173
HER2 positive subtype accounts for 20-30% of all breast cancers. HER2 positive breast
cancers are more aggressive, more likely to metastasize, and show increased resistance to
hormonal therapy.174 Adjuvant therapies that contained EGFR inhibitors, such as trastuzumab
and lapatinib have significantly improved the clinical outcomes in HER2 positive patients.174,46
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TNBCs constitute 15-20% of all the breast carcinomas, and are clinically defined as
tumors that lack immunohistochemical expression of estrogen receptors (ER), progesterone
receptors (PR) and HER2 overexpression.175,176 This infamous subtype of breast cancer is known
for its poor prognosis, aggressiveness, high rates of brain metastases and greater incidence of
early recurrence with median survival rate of approximately 1 year.175 Since TNBCs are
generally resistant to chemotherapy with currently no alternative treatments available to those
affected, it seems imperative to identify new molecular targets that these cells rely upon for
proliferation, differentiation and growth.171,176
Ruxolitinib
Manufactured by Novartis, ruxolitinib (INCB018424, Jakafi) is a selective inhibitor of
JAK1 and JAK2 with IC50 values of 3.3 and 2.8 nM, respectively. It was approved by the FDA in
November 2011 for the treatment of intermediate or high-risk myelofibrosis, and phase I/II
clinical trials have manifested its capability in the reduction of splenomegaly and alleviating the
disease-associated symptoms.177-179 Orally administered, ruxolitinib is absorbed rapidly and
reaches Cmax within 2 hours before undergoing metabolism by the hepatic CYP3A4 system with
its mean half-life within the range of 3-4 hours.177,179,180 The mean Cmax value for a single dose of
25mg of the drug was measured to be approximately 1093 nM.177,181 Throughout the clinical
studies, ruxolitinib was well tolerated by the patients who received a safe dose of 15 mg bid, and
the toxic effects have been limited to ecchymosis, anemia, dizziness and headache.177,179
Ruxolitinib binds in the ATP binding pocket of its targets, inhibiting both wild-type JAK1 and
JAK2 and mutant JAK2 V617F (a gain-of-function mutation commonly observed in
myelofibrosis).179 Clinical studies have also demonstrated that ruxolitinib, through inhibition of
JAK1 and JAK2, suppressed phosphorylated-STAT3 and -STAT5 resulting in a reduction in
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signal transduction and inflammatory cytokine levels, including IL-6, TNF α, and macrophage
inflammatory protein 1β.178,179

Figure 48. Chemical structure of ruxolitinib phosphate.182

Lapatinib
Developed by GlaxoSmithKline, lapatinib (GW-572016, Tykerb) is a selective inhibitor
of EGFR/ERBB-1 and Her-2/ERBB-2 signaling, with IC50 values of 10.2 and 9.8 nanomolar,
respectively.183-186 In January 2010, lapatinib was granted accelerated FDA approval to be used
in combination with letrozole for the treatment of postmenopausal women with hormone
receptor positive metastatic breast cancer that over-express ErbB-2 receptor (more information
available

at

http://www.cancer.gov/about-cancer/treatment/drugs/fda-lapatinib).

Lapatinib

exhibits reversible, non-covalent inhibition of EGFR and ErbB-2 by binding in the ATP-binding
cleft located on the intracellular kinase domain of these receptors.183 This leads to suppression of
signal transduction through downstream pathways, including Ras/MAPK, and PI3K/AKT
pathway, ultimately resulting in growth arrest or apoptosis of cancer cells.184 Lapatinib reaches
its plasma Cmax of nearly 4 μM 3-4 hours after the oral administration, and is metabolized mostly
by the hepatic CYP3A4 system. The elimination half-life of lapatinib is about 14 hours after
single dose administration.185 Lapatinib caused minimal toxic effects in patients who received a
daily dose of 1500 mg with the adverse events being limited to diarrhea, skin rash, and fatigue.186
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Figure 49. Chemical structure of lapatinib.185
Afatinib
Developed and manufactured by Boehringer Ingelheim, afatinib (BIBW2992, Gilotrif) is
an oral inhibitor of ERBB family of tyrosine kinases.187-189 It binds EGFR, ErbB2 and ErbB4
receptors with high selectivity with IC50 values of 0.5, 14 and 1nM, respectively.187,188 Afatinib
carries a Michael acceptor group, which allows for covalent binding to specific residues within
the ATP binding pocket of its targets, resulting in irreversible inhibition of receptor
autophosphorylation.188 It also blocks transphosphorylation of ErbB3.187 In the United States,
afatinib is approved for the treatment of patients with metastatic NSCLC whose tumors contain
EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.187 Afatinib is absorbed
relatively fast, with steady state being reached within 8 days.187,188 The mean half-life of afatinib
is 30-48 hours.188 It goes through minor hepatic metabolism, and is mainly eliminated via feces
(85%), and urine (4%).187 Afatinib caused minimal toxicity in patients who received a
recommended daily dose of 40 mg, with side effects being limited to rash and diarrhea.187,188

Figure 50. Chemical structure of Afatinib.188
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The drug Combination Rationale
EGFR amplification and overexpression is commonly observed in many breast cancers,
including 30-52% TNBC carcinomas.190,191 It has been well documented that the tumors with
alterations in EGFR receptor are more aggressive in nature and lead to more dismal clinical
outcome.82 Therefore, EGFR-targeted therapy in all types of breast carcinoma, including TNBC,
emerged as a promising approach with many agents such as cetuximab, trastuzumab and
lapatinib employed in numerous clinical trials.46,82,174 However, there is growing evidence that
inhibition of ErbB receptors as a monotherapy is not adequate for blocking the malignancy, and
the combination of targeted inhibitors will most likely present a more feasible approach.82
Prior studies have suggested a prominent role for cytokine receptor signaling through
JAK/STAT pathway in breast carcinogenesis, and prolactin, erythropoietin, and other cytokines
such as IL-6 and IL-11 have been linked to an increase in breast cancer incidence.192-195 In
addition, STAT3 and STAT5 activation have been shown to contribute significantly to the
induction of mammary carcinogenesis.196,197 Between the two, STAT3 acts as a point of
convergence for many well-known oncogenic pathways, and its role in promoting tumorigenesis
and drug resistance has been supported by numerous studies.198,199 However, no inhibitor of
STAT3 has been approved by FDA yet.198 Furthermore, EGFR and STAT signaling crosstalk
through different mechanisms.200 For instance, EGFR signaling can activate STAT3 in a process
mediated by Src family of kinases, and STAT3 has been demonstrated to upregulate ErbB2
transcription in metastatic HER2 positive breast cancer.83,201 These findings led us to hypothesize
that the concurrent inhibition of JAK/STAT and EGFR pathways would cause detrimental
effects in breast cancer cells. Since there are no FDA-approved STAT inhibitors available at the
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moment, and knowing that STAT3 and STAT5 are both heavily involved in breast cancer, we
repurposed ruxolitinib, a JAK1/2 inhibitor, as a novel therapeutic in treatment of breast cancer.
Hypothesis
Concurrent inhibition of JAK/STAT and EGFR signaling pathways induces cell death in
breast cancer cells, and profoundly reduces mammary tumor growth.

Table 2. Breast cancer cell lines used in this study.
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Results
Ruxolitinib and lapatinib synergize to kill breast cancer cells
Initial studies determined whether the ERBB1/2/4 inhibitor lapatinib (referred to as LAP
in the figures) interacted with the JAK1/2 inhibitor ruxolitinib (referred to as RUX in the figures)
to kill breast cancer cells. Our data indicated that lapatinib and ruxolitinib strongly interacted to
kill a variety of breast cancer cells, including cells from all three subtypes; triple negative
(SUM149PT, HCC38 and BT549), HER2 positive (BT474), and ER positive (MCF7) (Fig 51).
The synergistic interaction between ruxolitinib and lapatinib was determined by colony
formation assay. Median dose effect isobologram analysis to determine synergism of drug
interaction was carried out according to the methods of Chou and Talalay using the CalcuSyn
program.151 The data suggested that ruxolitinib and lapatinib interacted in a synergistic fashion to
kill SUM149PT cells, with combination index (CI) values significantly below 1.0 (Figure 52).
Next, using molecular tools, we defined which ERBB family members in different cell
types were responsible for the interaction of ERBB receptor inhibitors and ruxolitinib.
SUM149PT cells were isolated from an inflammatory breast cancer patient whose tumor was
defined as “triple negative” but which nevertheless in our hands expressed detectable basal levels
of ERBB1, ERBB2, ERBB3 and ERBB4 by immuno-fluorescence of cells fixed in situ. In
SUM149PT cells combined inhibition of ERBB1 and ERBB2 or ERBB1, ERBB2 and ERBB4
strongly enhanced ruxolitinib toxicity (Figure 53).
Ruxolitinib is claimed to be a specific inhibitor of the Janus kinases JAK1 and JAK2, but
does not block JAK3 or TYK2. Thus we next determined whether knockdown of JAK1 and
JAK2 could account for the effects of ruxolitinib. Knockdown of both JAK1 and JAK2 enhanced
the lethality of lapatinib (Figure 54).

130

51A

131

51B

Figure 51. Ruxolitinib and lapatinib interact to kill breast cancer cells. Indicated cells were
treated with vehicle (DMSO), ruxolitinib-phosphate (1.0 M), lapatinib tosylate (1.0 M) or the
drugs in combination. Cell viability was assessed 24 hours after drug exposure using a Hermes
Wiscan instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in VEH cells.
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Figure 52. CI values provide proof of synergy between ruxolitinib and lapatinib.
SUM149PT cells were plated (250-1500 cells/well) in sextuplicate, and were treated with vehicle
(DMSO), ruxolitinib (0.25-1.50 µM), lapatinib (0.25-1.50 µM), or with both drugs combined. 24
hours after drug exposure, the medium was changed and cells were cultured in fresh medium for
10-14 days. Cells were then fixed and stained with crystal violet, and colonies were counted.
Colony formation data were entered into the CalcuSyn program and CI values were determined.
Based on this method, a combination index value of < 1.00 indicates synergistic effect, a value of
1.00 indicates additivity, and a value of greater > 1.00 equates antagonism of action between the
drugs (n = 2; 12 individual wells per data point ± SEM).
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Figure 53. Inhibition of ERBB receptors enhances ruxolitinib toxicity. SUM149PT cells
were transfected with a scrambled siRNA (siSCR) or with siRNA molecules to knock down the
expression of ERBB1, ERBB2 and ERBB4 in combinations, as indicated in the figure. 24 hours
after transfection cells were treated with vehicle control or ruxolitinib (0.5, 1, or 2 M), as
indicated. Cell viability was assessed 24 hours after drug exposure using a Hermes Wiscan
instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in siSCR cells.
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Figure 54. Inhibition of JAK1 and JAK2 enhances lapatinib toxicity. SUM149PT cells were
transfected with a scrambled siRNA (siSCR) or with siRNA molecules to knock down the
expression of JAK1 and JAK2 in combination. 24 hours after transfection cells were treated with
vehicle control or lapatinib (1 or 2 M), as indicated. Cell viability was assessed 24 hours after
drug exposure using a Hermes Wiscan instrument (n = 3, ± SEM). *P< 0.05 greater than
corresponding value in siSCR cells.
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Ruxolitinib and lapatinib combination alter multiple survival signaling pathways
Ruxolitinib and lapatinib modulate the functions and activities of many intracellular
signal transduction pathways, and we next explored the impact our ruxolitinib based drug
combination had on cell signaling processes. In SUM149PT cells lapatinib and ruxolitinib
inhibited the phosphorylation of EGFR, STAT3 and STAT5, as would be expected based on
their declared kinase specificities (Figures 55). Drug combination treatment of SUM149PT cells
reduced activity within the ERK1/2, p65 NFB and AKT signaling pathways. The reduced
activities within those well described “protective” signal transduction pathways correlated with
reduced MCL-1 and Bcl-xL expression within 6 hours. The drug combination also increased the
phosphorylation of JNK. To further examine changes in cell signaling after drug exposure we
then made use of multiplex antibody array assays in a Bio-Rad MAGPIX machine (Figure 56A
and B). The combination of ruxolitinib and lapatinib decreased the expression of multiple
protective and pro-inflammatory cytokines, including CXCL1, IL-1β and IL-8, and as observed
using immunoblotting, inactivated ERK1/2, AKT and NFB signaling. In addition, the drug
combination also reduced the phosphorylation of BAD, CREB, p70S6K and PDGFRα.
Based on the survival pathways that were inhibited by the drug combination, we further
assessed if the inhibition of these pathways were involved in the induction of cell death. In
SUM149PT triple negative breast cancer cells, expression of an activated form of STAT3, an
activated form of AKT, an activated form of MEK1/2, an activated form of mTOR, or pretreating cells with JNK inhibitory peptide suppressed the lethality of the drug combination
(Figure 57).
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Figure 55. The LAP+RUX combination alters major signal transduction pathways.
SUM149PT cells were treated with vehicle (DMSO), ruxolitinib (1.0 µM), lapatinib (1.0 µM), or
the drug combination for 6 and 12 hours. Cells were lysed and expression of indicated proteins
was determined by immunoblotting.
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Figure 56. Multiplex analysis of SUM149PT cells treated with ruxolitinib, lapatinib or the
drug combination. (A) and (B) SUM149 cells were treated with vehicle (DMSO), ruxolitinib
(1.0 M), lapatinib (1.0 M) or the drugs in combination for 4h, for 8h and for 12h. At each time
point cells were lysed and clarified by centrifugation. Clarified tumor cell lysates were then
subjected to multiplex assays as described in the methods to detect the plasma levels of the
indicated cytokines and phosphorylation status of signal transduction proteins using a BIO-RAD
MAGPIX multiplex instrument (n = 3 ± SEM).
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Figure 57. Inhibition of JNK1/2 or activation of STAT3, AKT, mTOR, and
MEK1suppresses the LAP+RUX combination lethality. SUM149PT cells were transfected
with plasmids to express either empty vector (CMV), activated STAT3 (caSTAT3), activated
MEK1 (caMEK1), activated AKT (caAKT), or activated mTOR (ca mTOR). 24 hours after
transfection, cells were treated with vehicle (DMSO) or ruxolitinib (1.0 µM) + lapatinib (1.0
µM) combination. Cell viability was assessed 24 hours after drug exposure using a Hermes
Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than corresponding value in CMV cells. For
JNK1/2 inhibition, plated cells were treated with the JNK inhibitory peptide (JNK-IP) for 30
minutes before the drugs were added accordingly. The viability was determined in a similar way
using a Hermes Wiscan instrument.
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Ruxolitinib and lapatinib combination induces cell death via apoptosis, autophagy and
necroptosis
We next investigated the molecular mechanisms by which the combination of ruxolitinib
and lapatinib was killing tumor cells. Initial studies using pharmacologic tools demonstrated that
killing induced by the drug combination was suppressed by inhibition of RIP-1 (necroptosis;
necrostatin-1), PI3K (autophagy; 3-methyl adenine (3-MA)), and caspases (apoptosis; Z-VAD)
(Figure 58). Thus, we next determined whether the activation of intrinsic and extrinsic apoptotic
pathways was triggered in the drug combination-treated cells. Inhibition of caspase 8 (death
receptor signaling) by overexpression of c-FLIP-s did not significantly reduce the lethality of the
drug combination treatment. Inhibition of caspase signaling downstream of mitochondria by
expression of dominant negative caspase 9 partially suppressed the drug combination toxicity.
Overexpression of Bcl-xL or knockdown of either BAX or BAK strongly reduced drug
combination killing (Figures 59 and 60). Although knock down of PUMA or NOXA was
protective, the effect of either knockdown on maintaining cell viability was less than that of
inhibiting both BAX and BAK function together. Additionally, knockdown of BID and AIF
reduced the drug combination-mediated lethality (Figure 61).
AIF is a mitochondrial protein that is released into the cytoplasm upon a lethal stimulus,
and it then re-locates to the nucleus where it acts to promote a non-caspase dependent
fragmentation of the DNA.202 In unstimulated SUM149PT cells AIF co-localized with the
mitochondrial protein AAA+ ATPase protein ATAD3A but not with the nuclear protein eIF3A.
Six hours after treatment with the combination of ruxolitinib and lapatinib, the co-localization of
AIF with ATAD3A appeared to remain similar; however the association of AIF with eIF3A in
the nucleus had increased (Figure 62).
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Figure 58. The LAP+RUX combination induces cell death via apoptosis, autophagy and
necroptosis. Plated SUM149PT cells were pre-treated with necrostatin-1, 3-MA, or Z-VAD for
45 minutes and were then exposed to the drugs individually or in combination as indicated. Cell
viability was assessed 24 hours after drug exposure using a Hermes Wiscan instrument (n = 3, ±
SEM). *P< 0.05 lower than corresponding value in VEH cells.
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Figure 59. The LAP+RUX combination activates intrinsic apoptotic pathway. SUM149PT
cells were infected with recombinant adenoviruses to express empty vector (CMV), dominant
negative caspase 9 (DN casp 9), Bcl-xL, or c-FLIP-s. 24 hours after infection cells were treated
with vehicle (DMSO), or the combination of ruxolitinib (1.0 µM) and lapatinib (1.0 µM). Cell
viability was assessed 24 hours after drug exposure using a Hermes Wiscan instrument (n = 3, ±
SEM). *P< 0.05 lower than corresponding value in CMV cells.
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Figure 60. Knockdown of BAX and BAK significantly suppresses the LAP+RUX
combination lethality. SUM149PT cells were transfected with a control scrambled siRNA
(siSCR) or two different siRNAs to knockdown expression of BAX and BAK. 24 hours after
transfection cells were treated with vehicle (DMSO), or the combination of ruxolitinib (1.0 µM)
and lapatinib (1.0 µM). Cell viability was assessed 24 hours after drug exposure using a Hermes
Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than corresponding value in siSCR cells.
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Figure 61. Knockdown of PUMA, NOXA, BID and AIF reduces the LAP+RUX
combination lethality. SUM149PT cells were transfected with a control scrambled siRNA
(siSCR) or different siRNAs to knockdown expression of NOXA, PUMA, BID and AIF. 24
hours after transfection cells were treated with vehicle (DMSO), or the combination of
ruxolitinib (1.0 µM) and lapatinib (1.0 µM). Cell viability was assessed 24 hours after drug
exposure using a Hermes Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than corresponding
value in siSCR cells.
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Figure 62. AIF translocates to the nucleus 6 hours after drug exposure. SUM149PT cells
were treated with vehicle (DMSO), or the combination of ruxolitinib (1.0 µM) and lapatinib (1.0
µM) as indicated for 6 hours after which cells were fixed in place and permeabilized using 0.5%
Triton X100. Immuno-fluorescence was performed at 60X magnification to detect the colocalization levels of the indicated proteins, and for the total expression level of AIF.
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Based on the preliminary data from 3-MA-treated cells, and also knowing that
overexpression of mTOR was strongly protective, we next investigated the induction of
autophagy in SUM149PT cells in response to the drug combination. . Treatment of cells with the
combination of ruxolitinib and lapatinib increased the numbers of autophagosomes in cells in a
greater than additive fashion and in a time-dependent fashion (Figure 63). In agreement with our
preliminary data using 3-MA, knock down of Beclin1 or of ATG5 suppressed, but did not
completely abolish, tumor cell killing by the drug combination (Figure 64).
Of note, the treatment of cells with the drug combination caused LC3-GFP intense
staining vesicles to co-localize with the mitochondria, an indicator of mitophagy (Figure 65).
Treatment of cells with the combination of ruxolitinib and lapatinib also caused LC3-GFP
staining vesicles to co-localize with acidic lysosomes (Figure 66).
We next determined whether the induction of autophagosome formation was an essential
process for activation of BAX and BAK above the level of mitochondrial dysfunction or whether
it was a consequence downstream of an early form of mitochondrial dysfunction. Treatment of
SUM149 cells with the combination of ruxolitinib and lapatinib activated the toxic BH3 domain
proteins BAX and BAK (Figure 67). Activation of BAX was almost abolished by knockdown of
Beclin1 or of BID expression, whereas activation of BAK was only modestly impacted by BID
knockdown (Figure 67).
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Figure 63. The LAP+RUX combination increases autophagosome formation. SUM149 cells
were transfected with a plasmid to express LC3-GFP. Twenty four hours after transfection cells
were treated with vehicle (DMSO), lapatinib (1.0 M), ruxolitinib (1.0 M), or in combination
as indicated for 6 or 12 hours. At each time point cells were visualized using a fluorescent
microscope at X40 magnification and the mean number of intense punctate GFP positive vesicles
per cell determined in > 40 cells from random fields ± SEM (*p < 0.05 greater than lapatinib
alone or ruxolitinib alone treatments).
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Figure 64. Knockdown of Beclin1 and ATG5 reduces the lethality of the LAP+RUX
combination. SUM149PT cells were transfected with a control scrambled siRNA (siSCR) or
two different siRNAs to knockdown expression of Beclin1 and ATG5. 24 hours after
transfection cells were treated with vehicle (DMSO), or the combination of ruxolitinib (1.0 µM)
and lapatinib (1.0 µM). Cell viability was assessed 24 hours after drug exposure using a Hermes
Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than corresponding value in siSCR cells.
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Figure 65. The LAP+RUX combination induces mitophagy. SUM149PT cells were
transfected with a plasmid to express LC3-GFP. 24 hours after transfection cells were treated
with vehicle (DMSO), lapatinib (1 M), ruxolitinib (1 M) or in combination as indicated for 6
hours. Cells were then treated with MitoTracker Red CMXRos (25 nM) for 30 min. Cells were
visualized using a fluorescent microscope at 40X magnification in the red and green fluorescent
channels. The red and green images were merged in Adobe Photoshop CS6; areas of yellow
staining indicate the co-localization of GFP and MitoTracker Red staining.
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Figure 66. The LAP+RUX combination induces co-localization of autophagosomes to
lysosomes. SUM149PT cells were transfected with a plasmid to express LC3-GFP. 24 hours
after transfection cells were treated with vehicle (DMSO), lapatinib (1 M), ruxolitinib (1 M)
or in combination as indicated for 6 hours. Cells were then treated with LysoTracker Red DND99 (25 nM) for 30 min. Cells were visualized using a fluorescent microscope at 40X
magnification in the red and green fluorescent channels. The red and green images were merged
in Adobe Photoshop CS6; areas of yellow staining indicate the co-localization of GFP and
LysoTracker Red staining.
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Figure 67. Knockdown of Beclin1 abolishes activation of BAX and BAK. SUM149PT cells
were transfected with a scrambled nonsense siRNA molecule (siSCR), or siRNA molecules to
knockdown the expression of BID or of Beclin1. 24 hours after transfection cells were treated for
6 hours with vehicle (DMSO) or with ruxolitinib (1 M) and lapatinib (1 M) combination for 6
hours. Cells were isolated and broken down using CHAPS based lysis buffer with vigorous
trituration, followed by lysate clarification via centrifugation (5 min x 14,000 g). Equal protein
mass portions of lysates were immunoprecipitated using antibodies that recognize epitopes in
BAX and in BAK only open to detection when these toxic BH3 domain proteins are active. The
total expression of BAX and of BAK under each condition was assessed by immunoblotting.
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Discussion
This study was conducted to determine whether the concurrent inhibition of JAK/STAT
and ERBB signaling could synergize to kill breast cancer cells. As stated before, EGFR
amplification and overexpression is commonly observed in many breast cancers, including 3052% TNBC carcinomas.190,191 In addition, prior studies have suggested a prominent role for
cytokine receptor signaling through JAK/STAT pathway in breast carcinogenesis, and prolactin,
erythropoietin, and other cytokines such as IL-6 and IL-11 have been linked to an increase in
breast cancer incidence.192-195 Furthermore, EGFR and JAK/STAT signaling pathways have been
shown to crosstalk through different mechanisms.200 These reports led us to hypothesize that
concurrent inhibition of these two pathways could be a potent novel therapeutic approach in
treatment of breast cancer. Since there are no FDA-approved STAT inhibitors available at the
moment, and knowing that STAT3 and STAT5 are both heavily involved in breast
carcinogenesis, we repurposed ruxolitinib, a JAK1/2 inhibitor, as a novel therapeutic in treatment
of breast cancer.
Our initial data indicated that lapatinib and ruxolitinib strongly interacted to kill a variety
of breast cancer cells, including cells from all three subtypes; triple negative (SUM149PT,
HCC38 and BT549), HER2 positive (BT474), and ER positive (MCF7). Colony formation
assays and CI values were very well indicative of the synergistic interaction between the two
drugs. Moreover, using molecular tools, we demonstrated that the inhibition of ERBB receptors
and JAK1 and JAK2 is the major reason behind the strong interaction between these two kinase
inhibitors. Knockdown of ERBB1/2/4 in SUM149PT cells recapitulated the toxic interaction
with ruxolitinib. Similarly, combined knockdown of JAK1 and JAK2 could recapitulate the toxic
effects of ruxolitinib when combined with ERBB1/2/4 inhibitors.
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Lapatinib and ruxolitinib, as expected based on their declared kinase specificities,
inhibited the phosphorylation of EGFR, STAT3 and STAT5. Additionally, the combination of
the two drugs reduced activities within those well described survival signal transduction
pathways, such as ERK1/2, p65 NFB and AKT, which correlated with reduced MCL-1 and
Bcl-xL expression within 6 hours. Further unbiased multiplex analyses indicated that the
combination of ruxolitinib and lapatinib decreased the expression of multiple protective and proinflammatory cytokines, including CXCL1, IL-1β and IL-8, as well as the phosphorylation of
BAD, CREB, p70S6K and PDGFRα. Decreased phosphorylation of CREB, BAD and p70S6K
correlated with the decreased P-ERK1/2 and P-AKT as demonstrated by both immunoblotting
and multiplex assay. However, a decrease in PDGFRα phosphorylation, which was also observed
in cells treated with ruxolitinib alone, was somewhat unexpected, but could provide further
evidence as why these two kinase inhibitors interacted in such synergistic fashion. In agreement
with our data form multiplex assays and immunoblotting, overexpression of MEK1, STAT3,
AKT and Bcl-xL significantly protected the cells, further providing proof for involvement of
these inhibited signal transduction proteins in the induction of cell death. Studies to define the
downstream effectors of AKT, STAT3 and ERK1/2 signaling that regulate the threshold for cell
killing in the presence of ruxolitinib and lapatinib are outside the scope of the present
manuscript.
As p70S6K phosphorylation, an mTOR substrate, was reduced, and the expression of an
activated form of mTOR as well as pre-treating the cells with 3-MA strongly protected the cells,
we next investigated the role of autophagy in cell death. In accordance with 3-MA data, the
inhibition of Beclin1 and ATG5 significantly protected the cells. The drug combination
increased the number of the LC3-GFP vesicles in a greater than additive fashion, and the LC3-
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GFP vesicles were shown to co-localize to the acidic lysosomes in the combination-treated
group. We also discovered that the drug combination induced mitophagy, as the LC3-GFP
stained autophagosomes were shown to co-localize to the mitochondria.
Since pan-caspase inhibitor Z-VAD strongly suppressed the drug combination-mediated
lethality, we next determined if the extrinsic and intrinsic apoptotic pathways were activated by
the combination of ruxolitinib and lapatinib. The expression of dominant negative caspase 9
modestly protected the cells whereas the overexpression of c-FLIP-s did not protect the cells at
all. This was specifically interesting since the knockdown of BID, a substrate of caspase 8, was
strongly protective. The toxic BH3 domain protein BID is activated by proteolytic cleavage; a
cleavage most commonly thought to be catalyzed by caspases 8 and 10 downstream of death
receptors but also less commonly by cathepsin and calpain proteases released due to lysosomal
dysfunction/autophagy flux.203 More studies will be required to determine if the cleavage of BID
occurs through cathepsin and calpain proteases. We also demonstrated that the mitochondrial
permeabilization occurred through activation of BAX and BAK, which subsequently led to the
release of AIF and its translocation to the nucleus.
Furthermore, our data indicated that activation of BAX and BAK was dependent on
activation of autophagy and that the induction of autophagosome formation was an essential
process for activation of BAX and BAK above the level of mitochondrial dysfunction.
As ruxolitinib and lapatinib interacted in a synergistic fashion to kill a variety of breast
cancer types, we are planning to further expand our studies in the future by evaluating the
efficacy of the drug combination in vivo. We are also concurrently evaluating a potential
replacement of lapatinib with the more potent new generation ERBB inhibitor afatinib, which
irreversibly inactivates ERBB1/2/4 and also blocks transphosphorylation of ErbB3.
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Figure 68. Proposed mechanism of cell death induced by the combination of RUX and
LAP. The combination of ruxolitinib and lapatinib reduced the phosphorylation of AKT,
ERK1/2 and p65 NFB, which correlated with reduced MCL-1 and Bcl-xL expression. It also
induced cell death through activation of JNK. The drug combination induced cytotoxic
mitophagy, which acted upstream of the mitochondrial dysfunction, as Beclin1 mediated
activation of BAX and BAK. Cleavage of BID also occurred in response to the treatment with
the drug combination. As caspase 8 inhibition was not protective, we suspect that the cleavage of
BID could have been mediated by cathepsins and calpains. In addition, mitochondrial
dysfunction led to the release of AIF and its translocation to the nucleus. (Guide:
represents
explored pathways,
represents unexplored but feasible pathways)
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Conclusion
In conclusion, the combination of ruxolitinib and lapatinib interacted to kill a variety of
different breast cancer cells, including triple negative, HER2 positive and ER positive, in a
synergistic fashion. Using pharmacologic and molecular tools, we demonstrated that the killing
induced by the drug combination was mediated via necroptosis, apoptosis, and autophagy. We
also demonstrated that the inhibition of ERBB receptors and JAK1 and JAK2 is the major reason
behind the strong interaction between these two kinase inhibitors. Moreover, our data
demonstrated that the induction of autophagosome formation and mitophagy acted upstream of
the mitochondrial dysfunction, as knockdown of Beclin1 abolished BAX and BAK activation. In
addition, we showed that whereas the inhibition of caspase 8 was not protective, the knockdown
of BID significantly protected the cells. Therefore, this proteolytic cleavage of BID could be
mediated by the cathepsin and calpain proteases although more studies will be required to fully
elucidate the mechanism of BID activation. Our data also argued that the translocation of AIF
from mitochondria to the nucleus played a significant role in inducing cell death.
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CHAPTER 5: Concluding Remarks

The ultimate goal of the studies in this manuscript was to propose novel potent
combinatorial targeted therapies for the treatment of cancers of liver, colon and breast using
FDA-approved drugs. The aforementioned cancers are amongst the top five most prevalent and
most fatal worldwide. Currently, surgical resection, radiotherapy and adjuvant chemotherapy, in
some cases combined with certain approved targeted agents, constitute the front line therapies for
HCC and CRC. Likewise, breast cancer, based on its characteristics, is usually treated with the
combination of surgery, radiotherapy, chemotherapy, hormonal and targeted therapy.
The recent advancements in cancer genomics and identification of commonly mutated
oncogenes coupled with poor chemotherapy response rates have shifted cancer therapy towards a
more targeted approach based on better understanding of cancer biology.11 Evidently, unlike
chemotherapy, the major benefit of this type of tailored therapy is that it only interferes with
distinct molecular targets that the cancer cells physiologically depend on, thereby providing high
specificity, a broader therapeutic index, and less nonspecific toxicities.12 However, a major
setback to single-agent targeted therapy is the activation of parallel survival pathways. This
oncogenic bypass mechanism results in the cell activating an alternative survival pathway in the
event of blockade of a specific pathway; thus, leading to drug resistance.22,23 Recent clinical
trials have provided convincing evidence that the use of targeted therapeutics in combination
provides a more rational strategy to increase the efficacy of the treatments.11
Mutations in ras gene have been frequently observed in liver and colorectal cancers,
which led to approval of sorafenib and regorafenib for the treatment of HCC and CRC,
respectively. However, both drugs only produced modest effects with low response rates in the
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clinic.128,204 Therefore, our major aim in this study was to potentiate the effect of sorafenib
(SOR) and regorafenib (REGO) in these cancers by identifying/blocking another molecular
target that hepatoma and colon cancer cells rely upon to survive. Recent studies have reported
the elevated levels of PDE5 expression in many cancers including colon adenocarcinoma and
commonly used colon cancer cell lines HT29 and HCT116 cells.147,205 Activation of cGMP/PKG
pathway reduces cellular growth and induces apoptosis through induction of β-catenin, which
subsequently inhibits the function of multiple downstream survival proteins such as cyclin D1
and survivin.205 Thus, elevated levels of PDE5, the enzyme that hydrolyzes cGMP, has been
suggested to be involved in cancer progression.205 We alongside our colleagues at VCU had
previously reported the enhancing effect of PDE5 inhibitors in chemotherapy cell killing.145-147
In these studies PDE5 inhibitors, in a NOS-dependent fashion, were shown to enhance
chemotherapy effect through activation of CD95 receptors, the generation of ROS, and
mitochondrial dysfunction.145-147 As mentioned earlier in chapter 1, the cofactor BH4 plays a
critical role in NOS activity. Small ratio of BH4 relative to its oxidized form, BH2, causes NOS
uncoupling, leading to production of ROS and RNS rather than NO.87,89 New studies have
indicated that BH4:BH2 ratio is significantly lower in tumor cells than in normal tissue.206 Thus,
whereas sildenafil (SIL) is often associated with reduced oxidative stress in non-transformed
cells, it promotes oxidative stress in tumor cells.156 In agreement with these reports, we observed
a significant increase in ROS and RNS levels as early as 2 hours after drug exposure. Our results
suggested that the NOS activity and the ROS generation played a significant role in triggering a
cytotoxic form of autophagy, and mediating cell death through activation of CD95 death receptor
pathway. The crucial role of CD95 death receptor activation in [SOR/REGO+SIL]-mediated cell
death was very well elucidated via expression of wild type CD95 in CD95 null- HUH7 cells.
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Additionally, prior studies had indicated that the pro-apoptotic effect of cGMP/PKG pathway
was also mediated through JNK.205 Accordingly, our data showed an increase in phosphoJNK1/2 level in cells treated with REGO+SIL combination, and the pre-treatment of cells with
JNK inhibitory peptide almost abolished the drug combination toxicity. Moreover, our in vivo
tumor analysis revealed a significant increase in phospho-c-Jun level, which further approves the
pro-apoptotic role of JNK. Furthermore, the drug combination inhibited the AKT/mTOR
pathway, which was shown to play a major role in induction of cell death as the expression of an
activated form of mTOR significantly reduced the [SOR/REGO+SIL]-mediated lethality.
Reduction in phospho-AKT and phospho-mTOR levels could be the direct outcome of PDGFR
inhibition, which our laboratory has repeatedly shown to be a major target for SOR and REGO.
SOR and REGO also induced ER stress. These drugs rapidly down-regulated GRP78,
which resulted in a prolonged intense ER stress response leading to mitochondrial dysfunction.
In addition to GRP78, recent studies from our laboratory indicated that these multi-kinase
inhibitors interrupted the function of multiple other chaperones including HSP70, HSP90 and
HSP27. Inhibition of multiple chaperones by SOR and REGO in cancer cells, which generally
express more proteins than non-transformed cells and are heavily dependent on protein folding
machinery, adds up another layer to the broad anti-tumor effects of these drugs.207
Collectively, the lethal effect of SOR/REGO+SIL combination in vitro is primarily
mediated by the inhibition of multiple chaperones (induction of severe ER stress), the blockade
of PDGFR signaling (decreased AKT/mTOR signaling), The NOS-dependent generation of
ROS/RNS, pro-apoptotic function of JNK, and activation of CD95 death receptor signaling
pathway. This explains why this drug combination responded well in multiple genetically diverse
tumor cell types regardless of Ras mutation status.
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The toxic effect of this drug combination translated well into our mouse models carrying
pre-formed tumors as the combination of SOR+SIL and REGO+SIL profoundly reduced the
growth of HUH7 and HT29 tumors in vivo, respectively. In addition, the ex vivo colony
formation data revealed a significant reduction in plating efficiency of the cells treated with the
combination of REGO+SIL as compared to REGO alone, which further approves the enhancing
effect of PDE5 inhibition on REGO toxicity. Plus, the REGO+SIL combination-treated mice had
significantly lower levels of VEGF and angiopoietin in their blood serum compared with the
control group. The blockade of angiogenesis could be another way by which the drug
combination exerted its anti-tumor effect in the mouse models. Collectively, the drug
combination anti-tumor activity in vivo is likely an amalgamation of a direct anti-tumor cell
killing effect by the drug combination (as previously discussed), antiangiogenic capability of
SOR and REGO, inhibition of ABCB1/ABCG2 efflux pumps, and increased tumor vasculature
permeability caused by the actions of sildenafil on endothelial cells.
In order to further tailor this drug combination, we investigated the potential addition of a
third drug by searching for biomarkers for activated survival pathways. Prior studies from our
group had shown that SOR could increase the levels of ceramides in hepatoma cells.152 In this
study, REGO was noticed to have a similar effect on ceramides. REGO also increased the level
of S1P, a sphingolipid metabolite that regulates growth, survival, migration and angiogenesis.127
Initial in vitro studies indicated that the multiple sclerosis drug FTY720, an HDAC inhibitor and
S1P antagonist, enhanced the toxicity of REGO and REGO+SIL combination. However, to our
surprise, HT29 tumors in mice treated with FTY720 re-grew at a much faster rate after cessation
of drug treatment than either REGO alone or treatment with REGO+SIL, an effect seemingly to
be mediated by an increase in angiogenesis and tumor vascularization. Undoubtedly, FTY720
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possesses distinct anti-tumor activity as FTY720 treatment has been previously shown to block
colitis-associated cancer progression.149,150 However, our in vivo data demands further
investigation into its mechanism of action as FTY720 treatment led to a significant increase in
angiogenic/invasion regulatory cytokines.
In addition to S1P up-regulation, we also noticed a significant increase in phospho-AKT
as well as stable high EGFR phosphorylation in response to the drug combination in both HUH7
and HT29 tumors collected 7 days after the start of treatment. Inhibition of either AKT or EGFR
enhanced the lethality of REGO+SIL combination in vitro. Thus, activation of AKT and EGFR
seemed to be amongst the major compensatory survival pathways counteracting the toxicity of
SOR/REGO+SIL. It certainly requires further in vivo experiments to fully validate the effects of
AKT and EGFR inhibition on SOR/REGO+SIL combination toxicity.
Our in vitro and animal studies are now an open clinical trial (NCT02466802) where
patients with all solid tumors are receiving increasing doses of REGO+SIL once daily. We’re
hoping to be able to receive tumor and blood samples from the patients in order to analyze the
tumor cell response and changes in the regulatory cytokines.
The second study in this manuscript was a proposal of a potent combinatorial targeted
therapy for the treatment of all types of breast cancer, including the chemotherapy resistant,
highly metastatic triple negative subtype. The study was designed based on the growing evidence
supporting the role of STAT3 and STAT5 in breast cancer, and the heavy crosstalk between
JAK/STAT and ERBB signaling pathways.196-201 The effect of ERBB inhibitors as single agents,
in combination with chemotherapy, hormonal therapy, or other targeted agents have been
extensively studied in the past with some clinical trials yielding significant improvement over
conventional therapy.52,53,82,185 However, since there are no FDA-approved STAT inhibitors
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currently available on the market, concurrent inhibition of STAT and ERBB signaling have not
been examined before. In order to test this hypothesis, we utilized ruxolitinib (RUX), a JAK1/2
inhibitor, to suppress STAT3/5 activation. Thus, this study was undertaken to determine whether
the myelofibrosis medication RUX could be re-purposed as a solid tumor cancer therapeutic, and
synergize with ERBB inhibitor lapatinib (LAP) to kill breast cancer cells.
Our in vitro results indicated that RUX and LAP strongly interacted to kill a variety of
genetically diverse breast cancer cells, including cells from all three subtypes; triple negative,
HER2 positive, and ER positive. Colony formation assays and CI values were very well
indicative of the synergistic interaction between the two drugs. Moreover, using molecular tools,
we demonstrated that the inhibition of ERBB receptors and JAK1 and JAK2 is the major reason
behind the strong interaction between these two kinase inhibitors, which further supported our
hypothesis.
With regard to the mechanism of action of this drug combination, our studies strongly
argued that the rapid inactivation of the PI3K/AKT/mTOR pathway led to a significant increase
in autophagosome formation; autophagosomes that co-localized with mitochondria (mitophagy)
and with lysosomes (autolysosomes). PI3K/AKT inhibition was also associated with decreased
phosphorylation of pro-apoptotic protein BAD (S136), which allows BAD to heterodimerize
with Bcl-xL and Bcl-2, and trigger apoptosis.208 Furthermore, we noticed that activation of the
executioner toxic BH3 domain proteins BAX and BAK required increased Beclin1 expression
(autophagosome formation) and also the activation/cleavage of BID. In addition, we found that
the autophagy-BAX/BAK/BID-dependent AIF release from the mitochondria and its
translocation to the nucleus is one key mechanism by which the RUX+LAP combination was
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killing tumor cells. We have our in vivo studies underway to determine if the combination of
RUX and ERBB inhibitors become a potent therapy in the mouse models.
Our laboratory has constantly worked to identify new drug combinations that can be
translated into potent therapies in the clinic. Recently, in a completed phase I trial
(NCT01450384) proposed by our laboratory combining the anti-folate pemetrexed and SOR, 20
out of 33 patients had prolonged stable disease or tumor regression, with one complete response
and multiple partial responses.209 Further pre-clinical studies from our laboratory indicated that
ERBB signaling functioned as a major compensatory survival pathway activated in response to
SOR and pemetrexed, and that the addition of the pan ERBB inhibitor afatinib significantly
enhanced the lethality of this drug combination.209 We hope that the addition of afatinib to the
combination of pemetrexed and SOR would be explored in a new phase I trial as it would
provide us with invaluable information on the feasibility of tailoring targeted therapy.
Having had success in the clinical trials in the past, our studies presented in this
manuscript strongly argue that the combination of REGO+SIL and RUX+LAP can possess
significant therapeutic value in the clinic.
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Laboratory Skills









Fluorescent and confocal microscopy
Cell/tissue culture techniques: transfection, infection and drug treatment
Tumor cell isolation (PDX models)
Western blotting
Immunohistochemistry
PCR/ qPCR
Immunoprecipitation
Animal handling techniques (tumor implantation, oral gavage, intracranial/ intratracheal/ tail vein
injections and blood/organ collection)
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